Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 63
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The prognostic impact of SIGLEC5-induced impairment of CD8 + T cell activation in sepsis

  • Lozano-Rodríguez, Roberto
  • Avendaño-Ortíz, José
  • Montalbán-Hernández, Karla
  • Ruiz-Rodriguez, Juan Carlos|||0000-0001-7392-8617
  • Ferrer, Ricard|||0000-0002-4859-4747
  • Martín-Quirós, Alejandro
  • Maroun-Eid, Charbel
  • González-López, Juanjo|||0000-0003-2419-5909
  • Fàbrega-Santamaria, Anna|||0000-0002-3866-2291
  • Terrón-Arcos, Verónica
  • Gutiérrez-Fernández, María
  • Alonso-López, Elisa
  • Cubillos-Zapata, Carolina
  • Fernández Velasco, María|||0000-0002-3293-3046
  • Perez de Diego, Rebeca|||0000-0001-8426-8765
  • Pelegrín, Pablo|||0000-0002-9688-1804
  • García-Palenciano, Carlos
  • Cueto, Francisco J.
  • del Fresno, Carlos
  • López-Collazo, Eduardo
Sepsis is associated with T-cell exhaustion, which significantly reduces patient outcomes. Therefore, targeting of immune checkpoints (ICs) is deemed necessary for effective sepsis management. Here, we evaluated the role of SIGLEC5 as an IC ligand and explored its potential as a biomarker for sepsis. In vitro and in vivo assays were conducted to both analyse SIGLEC5's role as an IC ligand, as well as assess its impact on survival in sepsis. A multicentre prospective cohort study was conducted to evaluate the plasmatic soluble SIGLEC5 (sSIGLEC5) as a mortality predictor in the first 60 days after admission in sepsis patients. Recruitment included sepsis patients (n = 346), controls with systemic inflammatory response syndrome (n = 80), aneurism (n = 11), stroke (n = 16), and healthy volunteers (HVs, n = 100). SIGLEC5 expression on monocytes was increased by HIF1α and was higher in septic patients than in healthy volunteers after ex vivo LPS challenge. Furthermore, SIGLEC5-PSGL1 interaction inhibited CD8 + T-cell proliferation. Administration of sSIGLEC5r (0.8 mg/kg) had adverse effects in mouse endotoxemia models. Additionally, plasma sSIGLEC5 levels of septic patients were higher than HVs and ROC analysis revealed it as a mortality marker with an AUC of 0.713 (95% CI, 0.656-0.769; p < 0.0001). Kaplan-Meier survival curve showed a significant decrease in survival above the calculated cut-off (HR of 3.418, 95% CI, 2.380-4.907, p < 0.0001 by log-rank test) estimated by Youden Index (523.6 ng/mL). SIGLEC5 displays the hallmarks of an IC ligand, and plasma levels of sSIGLEC5 have been linked with increased mortality in septic patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Reduced blood EPAC1 protein levels as a marker of severe Coronary Artery Disease: The role of hypoxic foam cell-transformed smooth muscle cells

  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Polishuck, Anna
  • Samouillan, Valerie|||0000-0003-0571-3985
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Piñero, Janet|||0000-0003-1244-7654
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Sabidó, Eduard|||0000-0001-6506-7714
  • Leta, Rubén|||0000-0003-4691-381X
  • Viladés Medel, David|||0000-0002-3638-9703
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Background: Vascular smooth muscle cells loaded with cholesterol (foam-VSMCs) play a crucial role in the progression of human atherosclerosis. Exchange Protein Directly Activated by cAMP 1 (EPAC1) is a critical protein in the regulation of vascular tone, endothelial function, and inflammation. Our objectives were to identify proteins specifically secreted by foam human coronary VSMCs (foam-hcVSMC) to evaluate their potential as circulating biomarkers for diagnosing coronary artery disease (CAD), and to ascertain the mechanisms underlying their levels in the blood of patients with CAD. Methods and Results: Differential proteomics identified EPAC1 as a differential foamhcVSMC-secreted protein. Circulating EPAC1 levels were measured by ELISA in blood from 202 patients with suspected CAD who underwent coronary computed tomography angiography (CCTA). Blood EPAC1 levels were significantly lower in CAD patients compared to controls (p < 0.001). EPAC1 levels were reduced in both men and women with severe CAD (SIS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Álamo, Patricia|||0000-0003-0510-5701
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Mangues, Ranib
  • Alba Castellón, Lorena|||0000-0003-3449-7820
Background: Colorectal cancer (CRC) has traditionally been treated with genotoxic chemotherapy to activate pro-apoptotic proteins to induce anticancer effects. However, cancer cells develop resistance to apoptosis, which leads to recurrence and poor prognosis. Moreover, this kind of therapy has been shown to be highly toxic to healthy tissues and, therefore, to patients. To overcome this issue, we developed a self-assembly tumor-targeted nanoparticle, T22-DITOX-H6, that incorporates the T22 peptide (a CXCR4 ligand) to selectively target cells overexpressing CXCR4, fused to the catalytic domain of diphtheria toxin, that exhibits a potent cytotoxic effect on these CXCR4+ cancer cells that exhibits potent cytotoxic effects on CXCR4-overexpressing cancer cells through the activation of pyroptosis, an immunogenic type of cell death. Methods: Colorectal CXCR4-expressing tumor cells (CT26-CXCR4+) were implanted subcutaneously into immunocompetent mice to study the effects of T22-DITOX-H6 treatment on tumor growth, cell death and innate immune cell recruitment to the tumor. Results: Here, we demonstrated that the T22-DITOX-H6 nanoparticle selectively activated pyroptosis, an immunogenic cell death that differs from apoptosis, leading to cell death in CXCR4-expressing cells, without affecting the viability of CXCR4-lacking cells. In addition, the nanoparticle administered to tumor-bearing mice induced a local antitumor effect due to the selective activation of pyroptosis in CXCR4+ targeted cancer cells. Biochemical analysis of plasma and histological analysis of non-tumor tissues revealed no differences between the groups. Remarkably, pyroptosis activation stimulates eosinophil infiltration into the tumor microenvironment, an effect recently reported to have an anti-tumorigenic function. Conclusion: These results highlight the dual role of CXCR4-targeted cytotoxic nanoparticle in eliminating cancer cells and boosting the self-immune response without compromising healthy organs.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk of Treatment Failure and Death after Ablation in Hepatocellular Carcinoma Patients-A Multiparametric Prediction

  • Muñoz-Martínez, S.|||0000-0003-0663-0575
  • Sapena, Victor|||0000-0003-4379-6486
  • García Criado, Ángeles|||0000-0003-3536-4288
  • Darnell, Anna
  • Forner, Alejandro|||0000-0002-9014-4950
  • Belmonte, Ernest|||0000-0003-3572-9769
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Rimola, Jordi|||0000-0002-1814-4198
  • Soler-Perromat, Alexandre|||0000-0003-2531-2484
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Mauro, Ezequiel|||0000-0002-0757-7676
  • Ayuso, Carmen|||0000-0002-9606-6957
  • Ríos, José|||0000-0002-0716-8784
  • Bruix, Jordi|||0000-0002-9826-0753
  • Vilana, Ramon|||0000-0002-2249-1926
  • Reig, María|||0000-0002-5711-9534
Background: Ablation is a first-line treatment for Barcelona Clinic Liver Cancer (BCLC)-0/A hepatocellular carcinoma (HCC). However, there are scarce data about patients' outcomes after recurrence. The present study evaluates the impact of patient and tumor characteristics at baseline and at recurrence on the Clinical Decision-Making process. Methods: We evaluated BCLC-0/A patients treated with percutaneous ablation from January 2010 to November 2018. Clinical and radiological data such as age, tumor location at ablation, pattern of recurrence/progression, and comorbidities during follow-up were registered. Tumor location was divided into 'suboptimal' vs. 'optimal' locations for ablation. The Clinical Decision-Making was based on tumor burden, liver dysfunction, or comorbidities. The statistical analysis included the time-to-recurrence/progression, censoring at time of death, date of last follow-up or liver transplantation, and time-to-event was estimated by the Kaplan-Meier method and Cox regression models to evaluate the risk of an event of death and change of treatment strategy. Results: A total of 225 patients [39.1% BCLC-0 and 60.9% BCLC-A] were included, 190 had unifocal HCC and 82.6% were ≤3 cm. The complete response rate and median overall survival were 96% and 60.7 months. The HCC nodules number (Hazard Ratio-HR 3.1), Child-Pugh (HR 2.4), and Albumin-Bilirubin score (HR 3.2) were associated with increased risk of death during follow-up. HCC in 'suboptimal location' presented a shorter time to recurrence. When comorbidities prevented further loco-regional or systemic treatment, the risk of death was significantly increased (HR 2.0, p = 0.0369) in comparison to those who received treatment. Conclusions: These results expose the impact of non-liver comorbidities when considering treatment for recurrence after ablation in the real-world setting and in research trials. Ultimately, we identified an orphan population for which effective interventions are needed.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Nanotoxin induces in situ pyroptosis to sensitize αPD1 to ablate metastases in microsattellite stable colorectal cancer

  • Carrasco-Díaz, Luis Miguel|||0000-0003-0567-2802
  • Otero-Mateo, Marc
  • Álamo, Patricia|||0000-0003-0510-5701
  • Gallardo, Alberto|||0000-0002-2514-2027
  • Virgili Manrique, Anna Cristina|||0000-0001-9733-6034
  • Paez, David|||0000-0002-5596-6588
  • Voltà-Durán, Eric|||0000-0003-0017-8274
  • Villaverde, Antonio|||0000-0002-2615-4521
  • Vázquez, Esther|||0000-0003-1052-0424
  • Unzueta Elorza, Ugutz|||0000-0001-5119-2266
  • Casanova Rigat, Isolda|||0000-0002-1196-4724
  • Alba Castellón, Lorena|||0000-0003-3449-7820
  • Mangues, Ramon|||0000-0003-2661-9525
Nanomedicine has not generated anticancer immunotherapies because of insufficient targeted specificity, lack of immunity, and associated toxicity. We developed a T22-DITOX-H6 (TDX) nanotoxin to selectively release the diphtheria toxin in the cancer cells in immunosuppressed CXCR4-overexpressing (CXCR4 +) colorectal (CRC) models, inducing pyroptosis and anticancer effect. Microsatellite stable (MSS) CRC patients do not respond to current immunotherapy. Since pyroptosis is highly immunogenic, we treated with TDX immunocompetent CXCR4 + CT26 MSS metastatic CRC models to selectively deliver the toxin to induce in situ pyroptosis mediated by the activation of NLRP3, Caspase-1 GSDMD and IL-1β. In contrast to immunosuppressed, in situ pyroptosis by TDX in immunocompetent models trigger CD8 + T cell recruitment, activation and killing of cancer cells in tissues, mimicking the pyroptosis that the host induces to kill diphtheria-infected cells. The combination of TDX and αPD1 further increases CD8 + recruitment and perforin secretion, achieving a tissue-specific antimetastatic activity in mesentery, peritoneum, and lung, and especially in liver metastases, without systemic toxicity. This is the first time that a novel nanomedicine achieves local T cell activation and antimetastatic effect mediated by pyroptosis and immunogenic cell death, whereas the combination with αPD1 enhances T cell activation, reaching a synergistic response in MSS CRC models.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publicación Artículo científico (JournalArticle)

Harnessing Senolytics and PARP Inhibition to Expand the Antitumor Activity of CDK4/6 Inhibitors in Prostate Cancer

  • Brandariz, Julian
  • De Llobet, Lara
  • Esquefa, Victor
  • Aguilar, Daniel
  • Salca, Andrei
  • Arce-Gallego, Sara
  • Cresta Morgado, Pablo
  • Sole, Arnau
  • Agundez, Laura
  • Mir, Gisela
  • Castro, Natalia
  • Casals, Teresa
  • Oliveira, Anna
  • Casanova-Salas, Irene
  • Malumbres, Marcos
  • Morella-Aucejo, Ángela|||0000-0002-6357-949X
  • Bernardos Bau, Andrea|||0000-0002-3842-5771
  • Martínez-Máñez, Ramón|||0000-0001-5873-9674
[EN] Metastatic prostate cancer (mPC) is a lethal disease; most therapeutic options focus on androgen receptor signaling inhibition, but resistance eventually arises. Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) have shown antitumor efficacy in mPC preclinical models, but their efficacy in mPC clinical trials has been limited. We hypothesize that novel combination therapies designed leveraging mPC adaptation to CDK4/6i could lead to increased and sustained antitumor effect. In this study, we demonstrate in a range of in vitro and in vivo prostate cancer models, including patient-derived xenografts, that prostate cancer cells adopt a senescent phenotype upon CDK4/6 inhibition that can be selectively targeted using senolytic compounds. Notably, interrupting CDK4/6 inhibition in intermittent drug schedules prompts a rapid bypass of the senescent phenotype that is associated with a temporal downregulation of replisome proteins in Rb-proficient but not in Rb-deficient models, leading to DNA damage accumulation and replication stress following treatment withdrawal. This effect opens a window of opportunity for treatment with PARP inhibitors (PARPi): Although upfront combined inhibition of CDK4/6 and PARP1 had no antitumor effect, their sequential use adding PARPi upon CDK4/6i withdrawal and cell-cycle reentry results in major antitumor activity. Our findings underscore the potential of CDK4/6i in prostate cancer therapy, particularly when administered under biology-driven sequential use of senolytic therapy or PARPi. Such strategic interventions hold promise in overcoming resistance and enhancing treatment outcomes for patients with advanced prostate cancer and open avenues for repurposing CDK4/6i therapy in mPC., This work was funded by Fundacion AECC (grants PRYCO211023SERR and LABAE20019MATE), Instituto de Salud Carlos III (PI20/0058) and Fundacion FERO. S. Arce-Gallego and N. Herranz were supported by Instituto de Salud Carlos III through fellowships FI19/00280 and CP19/00170, respectively. I. Casanova-Salas is supported by a Prostate Cancer Foundation Young Investigator Award (24YOU12). J. Mateo is supported by the CRIS Cancer Foundation (grant TCL-2020-10) and a DoD Congressionally Directed Medical Research Programs Physician Science Award (PC220307). Vall d'Hebron Institute of Oncology authors would like to thank the Spanish State Agency for Research (Agencia Estatal de Investigacion) for the financial support under Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support on this research. We would like to thank the Vall d'Hebron Institute of Oncology High Technology Unit, especially Dr. Elena Serrano Carballal, for their assistance in designing and analyzing the imaging experiments. We also extend our thanks to Guadalupe Espadas-Garcia for conducting the proteomic analyses at the Centre de regulacio genomica/Universitat Pompeu Fabra Proteomics Unit, which is part of the Spanish National Infrastructure for Omics Technologies (ICTS Omicstech). Lastly, we would like to thank Paula Garcia Carrascosa for creating the illustrations featured in the manuscript figures.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Soluble ST2 as a new oxidative stress and inflammation marker in metabolic syndrome

  • Roy, Ignacio
  • Jover, Eva
  • Matilla Cuenca, Lara
  • Álvarez, Virginia
  • Fernández Celis, Amaya
  • Beunza, Maite
  • Escribano, Elena
  • Gaínza Calleja, Alicia
  • Sádaba Sagredo, Rafael
  • López Andrés, Natalia
Background: Metabolic syndrome (MS) is a complex and prevalent disorder. Oxidative stress and inflammation might contribute to the progression of MS. Soluble ST2 (sST2) is an attractive and druggable molecule that sits at the interface between inflammation, oxidative stress and fibrosis. This study aims to analyze the relationship among sST2, oxidative stress, inflammation and echocardiographic parameters in MS patients. Methods: Fifty-eight patients with MS were recruited and underwent physical, laboratory and transthoracic echocardiography examinations. Commercial ELISA and appropriate colorimetric assays were used to quantify serum levels of oxidative stress and inflammation markers and sST2. Results: Circulating sST2 was increased in MS patients and was significantly correlated with the oxidative stress markers nitrotyrosine and 8-hydroxy-2¿-deoxyguanosine as well as with peroxide levels. The inflammatory parameters interleukin-6, intercellular adhesion molecule-1 and myeloperoxidase were positively correlated with sST2. Noteworthy, sST2 was positively correlated with left ventricular mass, filling pressures and pulmonary arterial pressures. Conclusion: Circulating levels of sST2 are associated with oxidative stress and inflammation burden and may underlie the pathological remodeling and dysfunction of the heart in MS patients. Our results suggest that sST2 elevation precedes diastolic dysfunction, emerging as an attractive biotarget in MS., This research was funded by Miguel Servet Fellowship II contract [CP13/00221, 2018] (Natalia López-Andrés) from the “Instituto de Salud Carlos III-FEDER”; Fondo de Investigaciones Sanitarias [PI18/01875, 2018]; a PFIS PhD studentship [FI19/00302, 2020] (Lara Matilla); Postdoctoral Fellowship Sara Borrell [CD19/00251, 2020] (Eva Jover).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publicación Artículo científico (JournalArticle)

Characterization of the sex-specific pattern of angiogenesis and lymphangiogenesis in aortic stenosis

  • Matilla Cuenca, Lara
  • Martín Núñez, Ernesto
  • Garaikoetxea Zubillaga, Mattie
  • Navarro, Adela
  • Vico, Julieta Anabela
  • Arrieta Paniagua, Vanessa
  • García Peña, Amaia
  • Fernández Celis, Amaya
  • Gaínza Calleja, Alicia
  • Álvarez, Virginia
  • Sádaba Sagredo, Rafael
  • López Andrés, Natalia
  • Jover, Eva
Objective: We aim to analyze sex-related differences in angiogenesis and lymphangiogenesis in aortic valves (AVs) and valve interstitial cells (VICs) from aortic stenosis (AS) patients. Approach and Results: Totally 230 patients (59% men) with severe AS undergoing surgical valve replacement were recruited. The density of total neovessels was higher in AVs from men as compared to women. Both small and medium neovessels were more abundant in men's AVs. Accordingly, male AVs exhibited higher CD31 and VE-cadherin expressions. The levels of the pro-angiogenic markers, such as vascular endothelial growth factor (VEGF)-A, VEGF receptor (VEGFR)1, VEGFR2, insulin-like growth factor-binding protein-2 (IGFBP-2), interleukin (IL)-8, chemerin, and fibroblast growth factor (FGF)-7, were increased in AVs from men. Transforming growth factor-¿ expression was higher in male AVs. The expression of antiangiogenic molecules thrombospondin (Tsp)-1, endostatin, and CD36 was upregulated in male AVs, although the levels of Tsp-2, IL-4, IL-12p70, and chondromodulin-1 were similar between both sexes. The number of lymphatic vessels and the expression of the lymphangiogenic markers Lyve-1 and D2-40 was higher in men's AV as well as VEGF-C, VEGF-D, and VEGFR3. Multivariate analyses adjusted for confounders further validated the sex-dependent expression of these targets. VICs isolated from men's AVs secreted higher amounts of the pro-angiogenic factors, VEGF-A, VEGFR1, IGFBP-2, and FGF-7, as well as the pro-lymphangiogenic factors, VEGF-C, VEGF-D, and VEGFR3, than women without changes in antiangiogenic markers. Conclusion: Our data show that aberrant angiogenic and lymphangiogenic cues are over-represented in male AVs. Importantly, the VIC is a relevant source of multiple morphogens involved in angiogenesis and lymphangiogenesis likely endowing the AV of men with the predominant calcific AS phenotypes., This work was supported by a Miguel Servet contract (CP13/00221) and by Fondo de Investigaciones Sanitarias (PI18/01875; PI21/00280) from the Instituto de Salud Carlos III - FEDER. LM was supported by a PFIS Ph.D. studentship (FI19/00302). EJ was supported by a Sara Borrell postdoctoral fellowship (CD19/00251). EM-N was supported by a Margarita Salas postdoctoral fellowship (ULL-MS-P14). MG was supported by a Miguel Servet Foundation Ph.D. studentship.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Psychometric Properties and Confirmatory Factor Analysis of the Spanish Version of the Maudsley Violence Questionnaire among Adolescent Students

  • Pérez-Martínez, Vanesa
  • Sanchez-SanSegundo, Miriam
  • Ferrer-Cascales, Rosario
  • Lordan, Oriol
  • Bowes, Nicola
  • Vives-Cases, Carmen
  • Ferrer-Cascales, Rosario|||/items/af59398b-f91f-4da8-8fbb-b9774ee8776f
  • Pérez-Martínez, Vanesa|||/items/8f46fff1-073d-4979-b8c2-5c9972b9e12d
  • Sanchez-SanSegundo, Miriam|||/items/6568386a-f3ed-44cf-9a26-8a0451062150
  • Vives-Cases, Carmen|||/items/0ca95232-58c2-4a62-8cc2-1dd2d1397ed7
The Maudsley Violence Questionnaire (MVQ) is an instrument specifically developed to evaluate violent thinking through two subscales examining macho attitudes and the acceptance of violence. This study analyzed the psychometric properties and factor structure of the Spanish version of the MVQ questionnaire in a large sample of 1933 Spanish adolescents. An online questionnaire was used to collect variables, such as sociodemographic and sexism data. The factor structure showed good fit indices in Spanish adolescents, which were similar to the original scale. The exploratory analysis yielded a first factor that explained 11.3% of the total variance and a second factor that explained 10.8% of the total variance. The Goodness of Fit Index (GFI) (0.902), Adjusted Goodness of Fit Index (AGFI) (0.90), Normed Fit Index (NNFI) (0.85), and the Comparative Fit Index (CFI) (0.86) suggested that the model fit the data adequately (with values ≥ 0.90) and the Root Mean Square Error of Approximation (RMSEA) (≤0.10) values indicative of an adequate fit. This study contributes a Spanish-language validated tool to measure machismo and the acceptance of violence among adolescents.
RUA. Repositorio Institucional de la Universidad de Alicante
Publicación Otros (Other)

Positive Masculinities and Gender-Based Violence Educational Interventions Among Young People: A Systematic Review

  • Pérez-Martínez, Vanesa
  • Marcos-Marcos, Jorge
  • Cerdán-Torregrosa, Ariadna
  • Briones Vozmediano, Erica
  • Sanz-Barbero, Belen
  • Davó-Blanes, M. Carmen
  • Daoud, Nihaya
  • Edwards, Claire
  • Salazar, Mariano
  • La Parra-Casado, Daniel
  • Vives-Cases, Carmen
  • Cerdán-Torregrosa, Ariadna|||/items/ec71f4af-f21c-4151-86c5-f98f86e01222
  • Davó-Blanes, M. Carmen|||/items/873e9c26-4d12-4d86-91bc-4decf9ce0c1c
  • La Parra-Casado, Daniel|||/items/a8493ce9-edf5-4538-a641-b339823b34bb
  • Marcos-Marcos, Jorge|||/items/03d1e88a-4203-485f-8a7c-6136db4bb188
  • Pérez-Martínez, Vanesa|||/items/8f46fff1-073d-4979-b8c2-5c9972b9e12d
  • Vives-Cases, Carmen|||/items/0ca95232-58c2-4a62-8cc2-1dd2d1397ed7
Background: Hegemonic masculinity has been recognized as contributing to the perpetration of different forms of gender-based violence (GBV). Abandoning hegemonic masculinities and promoting positive masculinities are both strategies used by interventions that foreground a “gender-transformative approach.” Preventing GBV among young people could be strengthened by engaging young men. In this article, we aim to systematically review the primary characteristics, methodological quality, and results of published evaluation studies of educational interventions that aim to prevent different forms of GBV through addressing hegemonic masculinities among young people. Main body: We conducted a systematic review of available literature (2008–2019) using Medline (PubMed), Scopus, Web of Science, PsycInfo, the CINAHL Complete Database, and ERIC as well as Google scholar. The Template for Intervention Description and Replication was used for data extraction, and the quality of the selected studies was analyzed using the Mixed Method Appraisal Tool. More than half of the studies were conducted in Africa (n = 10/15) and many were randomized controlled trials (n = 8/15). Most of the studies with quantitative and qualitative methodologies (n = 12/15) reported a decrease in physical GBV and/or sexual violence perpetration/victimization (n = 6/15). Longitudinal studies reported consistent results over time. Conclusions: Our results highlight the importance of using a gender-transformative approach in educational interventions to engage young people in critical thinking about hegemonic masculinity and to prevent GBV.
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Epigenomic Analysis Reveals a Unique DNA Methylation Program of Metastasis-Competent Circulating Tumor Cells in Colorectal Cancer

  • Bao-Caamano, Aida
  • Costa-Fraga, Nicolás
  • Cayrefourcq, Laure
  • Jácome, M. A.
  • Rodríguez-Casanova, Aitor
  • Muinelo Romay, Laura
  • López-López, Rafael
  • Alix-Panabières, Catherine
  • Díaz-Lagares, Ángel
[Abstract] Circulating tumor cells (CTCs) and epigenetic alterations are involved in the development of metastasis from solid tumors, such as colorectal cancer (CRC). The aim of this study was to characterize the DNA methylation profile of metastasis-competent CTCs in CRC. The DNA methylome of the human CRC-derived cell line CTC-MCC-41 was analyzed and compared with primary (HT29, Caco2, HCT116, RKO) and metastatic (SW620 and COLO205) CRC cells. The association between methylation and the transcriptional profile of CTC-MCC-41 was also evaluated. Differentially methylated CpGs were validated with pyrosequencing and qMSP. Compared to primary and metastatic CRC cells, the methylation profile of CTC-MCC-41 was globally different and characterized by a slight predominance of hypomethylated CpGs mainly distributed in CpG-poor regions. Promoter CpG islands and shore regions of CTC-MCC-41 displayed a unique methylation profile that was associated with the transcriptional program and relevant cancer pathways, mainly Wnt signaling. The epigenetic regulation of relevant genes in CTC-MCC-41 was validated. This study provides new insights into the epigenomic landscape of metastasis-competent CTCs, revealing biological information for metastasis development, as well as new potential biomarkers and therapeutic targets for CRC patients., This research was funded by the ISCIII (PI18/00307) and the European Regional Development Fund (FEDER), and by the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. We would like to thank all donors who participated in the Liquid Biopsy Crowdfunding campaign organized by ONCOMET in 2017. AB-C is funded by a predoctoral contract PFIS (FI19/00240) from “Instituto de Salud Carlos III” (ISCIII) co-funded by “Fondo Social Europeo” (FSE). NC-F is funded by a predoctoral contract from “Xunta de Galicia” (IN606A-2020/004). AR-C is supported by the Roche-Chus Joint Unit (IN853B 2018/03) funded by “Axencia Galega de Innovación (GAIN), Vicepresidencia Segunda e Consellería de Economía, Empresa e Innovación”. LM-R is funded by a contract “Miguel Servet” from ISCIII (CP20/00129). CA-P is supported by funding from the European Union Horizon 2020 Research and Innovation program under the Marie Skłodowska-Curie grant agreement No. 765492, by The National Institute of Cancer (INCa, http://www.e-cancer.fr), SIRIC Montpellier Cancer Grant INCa_Inserm_DGOS_12553, and the ERA-NET TRANSCAN 2 JTC 2016 PROLIPSY, la Fondation ARC pour la Recherche sur le cancer and les Fonds de dotation AFER pour la recherche médicale. AD-L was funded by a contract “Juan Rodés” (JR17/00016) from “Instituto de Salud Carlos III” (ISCIII) and by Servizo Galego de Saúde (SERGAS). All authors have read the journal's policy on disclosure of potential conflicts of interest, and have disclosed any financial or personal relationship with organizations that could potentially be perceived as influencing the described research, Xunta de Galicia; IN606A-2020/004, Xunta de Galicia; IN853B 2018/03, Francia. Institut National du Cancer; INCa_Inserm_DGOS_12553
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Microbiological factors and patient-reported outcomes of exacerbation burden in Pseudomonas aeruginosa-colonised bronchiectasis: A one-year prospective study

  • Bueno Freire, Leticia
  • Oscanoa Huamán, Patricia Elena
  • Lopez-Aladid, Ruben
  • Alcaraz-Serrano, Victoria
  • Vázquez, Nil
  • Cabrera, Roberto
  • Gabarrús, Albert
  • Ceccato, Adrian
  • Ferrer, Miguel
  • Soler, Néstor
  • Torres, Antoni
  • Fernandez Barat, Laia
Background: Exacerbations are key determinants of disease progression and impaired health-related quality of life (HRQoL) in non-cystic fibrosis bronchiectasis (BE). Despite the recognised association between Pseudomonas aeruginosa (PA) and worse outcomes, factors driving exacerbation burden remain poorly characterised. In patients with PA-colonised BE, we aimed to assess whether microbiological factors, including colonisation status and PA phenotype, together with HRQoL domains and respiratory symptoms, were associated with time to first exacerbation, exacerbation severity, and post-exacerbation changes in HRQoL. Materials and Methods: This prospective longitudinal study followed PA-colonised BE adults for 12 months with quarterly stable-state assessments focussing on time and severity of first exacerbation. HRQoL was measured by the Quality of Life Questionnaire-Bronchiectasis (QOL-B). Multivariable Cox, Firth penalised logistic, and ANCOVA models were fitted in R. Results: A total of 68 patients were included. During follow-up, 52 patients (76.5%) experienced ≥1 exacerbation, including 14 (26.9%) whose first event required hospitalisation. Neither colonisation status nor PA phenotype were associated with exacerbation risk or hospitalisation. Better daytime cough (HR 0.63, 95%CI 0.41–0.97; p = 0.036) and dyspnoea while talking (HR 0.47, 95%CI 0.26–0.87; p = 0.016) were independently associated with lower exacerbation risk. Lower exertional dyspnoea burden (OR 0.29, 95%CI 0.10–0.67; p = 0.003) and lower sputum quantity (OR 0.46, 95%CI 0.19–0.93; p = 0.030) were associated with lower odds of hospitalisation, together with poorer Vitality, Social Functioning, and Health Perceptions. After exacerbation, Social Functioning declined significantly (Δ −7.50 points, 95%CI −14.87 to −0.14; p = 0.046) and mucoid PA was independently associated with worse Emotional Functioning (β −15.64, 95%CI −27.89 to −3.39; p = 0.013). Conclusions: In PA-colonised BE, selected respiratory symptoms and HRQoL domains were associated with exacerbation burden, whereas microbiological characteristics showed no clear associations with exacerbation risk or hospitalisation, supporting the incorporation of patient-reported outcomes into longitudinal assessment., info:eu-repo/semantics/publishedVersion
Helvia. Repositorio Institucional de la Universidad de Córdoba
Publicación Artículo científico (JournalArticle)

Early release of circulating tumor cells after transarterial chemoembolization hinders therapeutic response in patients with hepatocellular carcinoma

  • Espejo-Cruz, María Lola
  • González Rubio, Sandra
  • Espejo, Juan J.
  • Zamora-Olaya, Javier
  • Prieto-Torre, María
  • Linares Luna, Clara Isabel
  • Ruiz Ramas, Álvaro
  • Jiménez Arranz, Álvaro
  • Guerrero-Misas, Marta
  • Barrera-Baena, Pilar
  • Poyato-González, Antonio
  • Montero Álvarez, José Luis
  • Sánchez-Frías, Marina
  • Ayllón, Maria Dolores
  • Rodríguez-Perálvarez, Manuel
  • De la Mata García, Manuel
  • Ferrín Sánchez, Gustavo
Background: Transarterial chemoembolization (TACE) is the first-line therapeutic option for patients with intermediate-stage hepatocellular carcinoma (HCC). Tumor neovascularization allows tumor growth and may facilitate the release of circulating tumor cells (CTCs) to the bloodstream after TACE. We investigated the relationship between early release of CTCs and radiological response after TACE. Methods: Prospective, single-center study including patients with HCC undergoing a first TACE from January 2019 to June 2023. The IsoFlux® system was used to evaluate EpCAM+ CTCs counts before TACE, at day 1 (D1), and at day 30 after TACE. Radiological response to TACE was assessed according to the mRECIST criteria one month after the procedure. Tumor vascularity was assessed by an interventional radiologist. Results: In all, 48 patients with HCC undergoing TACE were included (age 64.2±7.6 years, 14.6% women). CTC levels increased at D1 (114.0% [IQR 76.5%-178.0%], p=0.019) and normalized to baseline levels in the first month after TACE (76.5% [IQR 41.3%-131.8%], p=0.263). Higher CTC counts at baseline (p=0.009) and at D1 (p=0.026) were associated with tumor hypervascularity. Larger tumor size [OR: 1.9 (95% CI: 1.1-3.3), p=0.020] and CTC increase at D1 [OR: 5.3 (95% CI: 1.3-21.0), p=0.017] were independent predictors of non-response to TACE, especially for those patients with hypervascular lesions. Conclusions: A meaningful release of CTCs 24 hours after TACE was associated with suboptimal tumor response one month after the procedure. Future studies should evaluate the role of CTC dynamics to select candidates for adjuvant therapy after TACE and to analyze their impact on long-term outcomes.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation

  • Ramos-Hernández, Iris
  • Fuster-García, Carla
  • Aguilar-González, Araceli
  • Lozano-Vinagre, María L.
  • Guenechea-Amurrio, Guillermo
  • Sánchez-Luque, Francisco J.
  • Gonçalves, Manuel A. F. V.
  • Cathomen, Toni
  • Muñoz, P.
  • Molina-Estévez, Francisco J.
  • Martín, Francisco
To improve ex vivo gene therapy strategies involving hematopoietic stem and progenitor cells (HSPCs), we propose a novel knock-in strategy (named KI-Ep) aiming to achieve transgene regulation of the inserted cassette through the acquisition of naturally occurring epigenetic marks. Based on this hypothesis, we selected CX3CR1 (a myeloid-specific gene presenting a poised histone signature on primitive HSPCs) as safe harbor to generate KI-Ep HSPCs. We demonstrated that, unlike the expression pattern achieved with lentiviral vectors (LVs), the insertion of a constitutive expression cassette into the intron 1 of the CX3CR1 locus (CX3CR1-I) in HSPCs resulted in very low expression levels in the more primitive HSPCs but, crucially, strong expression in HSPC-differentiated populations (especially myeloid cells), both in vitro and in vivo. Furthermore, we showed that the promoter of the expression cassette inserted into CX3CR1-I acquired epigenetic marks associated with poised genes during the HSPC stage. These marks transitioned to activated histone states upon KI-Ep HSPCs differentiation. In summary, here, we introduce the KI-Ep concept which enables the epigenetic modulation of the inserted transgene during the HSPCs stem cell stages and its subsequent activation upon differentiation., This work was supported by the by the Fondo Europeo de Desarrollo Regional (FEDER), NextGenerationEU funds—actions of the Recovery and Resilience Mechanism and the Instituto de Salud Carlos III (ISCIII) through the financing research projects [PI18/00337 and PI21/00298 to F.M., and PI21/00875 to P.M.], networks (RICORS-TerAv [RD21/ 0017/0004 to F.M., P.M. and F-J.M-E.; RD21/0017/0027 to G.G-A.] and personal (FI19/00163 to I.R-H.). By the Consejería de Salud y Familias (Junta de Andalucía), under the 2019 call for “Proyectos Estratégicos I + D + I con incorporación de capital humano” [PEER-0286-2019 to P.M.] and FEDER/European Cohesion Fund (FSE) for Andalucía [PECART-0031-2020 to F.M.]; by the Consejería de Transformación Económica, Industria, Conocimiento y Universidades (Junta de Andalucía) through the EMERGIA EMERGIA2020 programe [EMERGIA20_00049 to P.M.]. By the Pompe Competitive Research Grant Program by SPARK Therapeutics [SPARK-2022-002 to F-J.M-E.]; by the Ministerio de Ciencia, Innovación y Universidades [PID2021-125077OB-C22 to G.G-A]; the Ministerio de Ciencia e innovación (MICIN)—líneas estratégicas [PLEC2021-008094 to F.M.] by Ministerio de Ciencia e innovación (MICIN), Plan de Recuperación, transformación y resilencia, Centro para el Desarrollo Tecnológico Industrial (CDTI) and European Union-Next Generation EU [00123009/SNEO-20191072 and PMPTA22/00060 to F.M.]; by the Spanish National Research Agency [AEI; grants RYC2021-031920-I and CNS2022-136033 to F-J.S-L.]. And by the European Union, Horizon Europe Framework Program through the EIC PathfinderChallenges [X-PAND 101070950 to T.C] and the European Cooperation in Science and Technology (COST) [GeneHumdi-CA21113]. Funding to pay the Open Access publication charges for this article was provided by Instituto de Salud Carlos III (ISCIII) [RD21/ 0017/0004]; Universidad de Granada/CBUA., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Thermal liquid biopsy (TLB) focused on benign and premalignant pancreatic cyst diagnosis

  • Hermoso-Durán, S.
  • García-Rayado, G.
  • Ceballos-Laita, L.
  • Sostres, C.
  • Vega, S.
  • Millastre, J.
  • Sánchez-Gracia, O.
  • Ojeda, J.L.
  • Lanas, Á.
  • Velázquez-Campoy, A.
  • Abian, O.
Background: Current efforts in the identification of new biomarkers are directed towards an accurate differentiation between benign and premalignant cysts. Thermal Liquid Biopsy (TLB) has been previously applied to inflammatory and tumor diseases and could offer an interesting point of view in this type of pathology. Methods: In this work, twenty patients (12 males and 8 females, average ages 62) diagnosed with a pancreatic cyst benign (10) and premalignant (10) cyst lesions were recruited, and biological samples were obtained during the endoscopic ultrasonography procedure. Results: Proteomic content of cyst liquid samples was studied and several common proteins in the different groups were identified. TLB cyst liquid profiles reflected protein content. Also, TLB serum score was able to discriminate between healthy and cysts patients (71% sensitivity and 98% specificity) and between benign and premalignant cysts (75% sensitivity and 67% specificity). Conclusions: TLB analysis of plasmatic serum sample, a quick, simple and non-invasive technique that can be easily implemented, reports valuable information on the observed pancreatic lesion. These preliminary results set the basis for a larger study to refine TLB serum score and move closer to the clinical application of TLB providing useful information to the gastroenterologist during patient diagnosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Chronic lymphocytic leukemia patients with IGH translocations are characterized by a distinct genetic landscape with prognostic implications

  • Pérez-Carretero, C.
  • Hernández-Sánchez, M.
  • González, T.
  • Quijada-Álamo, M.
  • Martín-Izquierdo, M.
  • Hernández-Sánchez, J.M.
  • Vidal, M.J.
  • de Coca, A.G.
  • Aguilar, C.
  • Vargas-Pabón, M.
  • Alonso, S.
  • Sierra, M.
  • Rubio-Martínez, A.
  • Dávila, J.
  • Díaz-Valdés, J.R.
  • Queizán, J.A.
  • Hernández-Rivas, J.Á.
  • Benito, R.
  • Rodríguez-Vicente, A.E.
  • Hernández-Rivas, J.M.
Chromosome 14q32 rearrangements/translocations involving the immunoglobulin heavy chain (IGH) are rarely detected in chronic lymphocytic leukemia (CLL). The prognostic significance of the IGH translocation is controversial and its mutational profile remains unknown. Here, we present for the first time a comprehensive next-generation sequencing (NGS) analysis of 46 CLL patients with IGH rearrangement (IGHR-CLLs) and we demonstrate that IGHR-CLLs have a distinct mutational profile with recurrent mutations in NOTCH1, IGLL5, POT1, BCL2, FBXW7, ZMYM3, MGA, BRAF and HIST1H1E genes. Interestingly, BCL2 and FBXW7 mutations were significantly associated with this subgroup and almost half of BCL2, IGLL5 and HISTH1E mutations reported were previously identified in non-Hodgkin lymphomas. Notably, IGH/BCL2 rearrangements were associated with a lower mutation frequency and carried BCL2 and IGLL5 mutations, while the other IGHR-CLLs had mutations in genes related to poor prognosis (NOTCH1, SF3B1 and TP53) and shorter time to first treatment (TFT). Moreover, IGHR-CLLs patients showed a shorter TFT than CLL patients carrying 13q-, normal fluorescence in situ hybridization (FISH) and +12 CLL, being this prognosis particularly poor when NOTCH1, SF3B1, TP53, BIRC3 and BRAF were also mutated. The presence of these mutations not only was an independent risk factor within IGHR-CLLs, but also refined the prognosis of low-risk cytogenetic patients (13q-/normal FISH). Hence, our study demonstrates that IGHR-CLLs have a distinct mutational profile from the majority of CLLs and highlights the relevance of incorporating NGS and the status of IGH by FISH analysis to refine the risk-stratification CLL model.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Body mass index interacts with a genetic-risk score for depression increasing the risk of the disease in high-susceptibility individuals

  • Anguita-Ruiz, Augusto
  • Zarza-Rebollo, Juan Antonio
  • Pérez-Gutiérrez, Ana M.
  • Molina, Esther
  • Gutiérrez, Blanca
  • Bellón, Juan Ángel
  • Moreno-Peral, Patricia
  • Conejo-Cerón, Sonia
  • Aiarzagüena, Jose María
  • Ballesta-Rodríguez, M. Isabel
  • Fernández, Anna
  • Fernández-Alonso, Carmen
  • Martín-Pérez, Carlos
  • Montón-Franco, Carmen
  • Rodríguez-Bayón, Antonina
  • Torres-Martos, Álvaro
  • López-Isac, Elena
  • Cervilla, Jorge
  • Rivera, Margarita
Depression is strongly associated with obesity among other chronic physical diseases. The latest mega- and meta-analysis of genome-wide association studies have identified multiple risk loci robustly associated with depression. In this study, we aimed to investigate whether a genetic-risk score (GRS) combining multiple depression risk single nucleotide polymorphisms (SNPs) might have utility in the prediction of this disorder in individuals with obesity. A total of 30 depression-associated SNPs were included in a GRS to predict the risk of depression in a large case-control sample from the Spanish PredictD-CCRT study, a national multicentre, randomized controlled trial, which included 104 cases of depression and 1546 controls. An unweighted GRS was calculated as a summation of the number of risk alleles for depression and incorporated into several logistic regression models with depression status as the main outcome. Constructed models were trained and evaluated in the whole recruited sample. Non-genetic-risk factors were combined with the GRS in several ways across the five predictive models in order to improve predictive ability. An enrichment functional analysis was finally conducted with the aim of providing a general understanding of the biological pathways mapped by analyzed SNPs. We found that an unweighted GRS based on 30 risk loci was significantly associated with a higher risk of depression. Although the GRS itself explained a small amount of variance of depression, we found a significant improvement in the prediction of depression after including some non-genetic-risk factors into the models. The highest predictive ability for depression was achieved when the model included an interaction term between the GRS and the body mass index (BMI), apart from the inclusion of classical demographic information as marginal terms (AUC = 0.71, 95% CI = [0.65, 0.76]). Functional analyses on the 30 SNPs composing the GRS revealed an over-representation of the mapped genes in signaling pathways involved in processes such as extracellular remodeling, proinflammatory regulatory mechanisms, and circadian rhythm alterations. Although the GRS on its own explained a small amount of variance of depression, a significant novel feature of this study is that including non-genetic-risk factors such as BMI together with a GRS came close to the conventional threshold for clinical utility used in ROC analysis and improves the prediction of depression. In this study, the highest predictive ability was achieved by the model combining the GRS and the BMI under an interaction term. Particularly, BMI was identified as a trigger-like risk factor for depression acting in a concerted way with the GRS component. This is an interesting finding since it suggests the existence of a risk overlap between both diseases, and the need for individual depression genetics-risk evaluation in subjects with obesity. This research has therefore potential clinical implications and set the basis for future research directions in exploring the link between depression and obesity-associated disorders. While it is likely that future genome-wide studies with large samples will detect novel genetic variants associated with depression, it seems clear that a combination of genetics and non-genetic information (such is the case of obesity status and other depression comorbidities) will still be needed for the optimization prediction of depression in high-susceptibility individuals.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Bowel preparation for colonoscopy changes serum composition as detected by thermal liquid biopsy and fluorescence spectroscopy

  • Hermoso-Durán, S.
  • Domper-Arnal, M. J.
  • Roncales, P.
  • Vega, S.
  • Sánchez-Gracia, Ó.
  • Ojeda, J. L.
  • Lanas, Á.
  • Velázquez-Campoy, A.
  • Abian, O.
(1) Background: About 50% of prescribed colonoscopies report no pathological findings. A secondary screening test after fecal immunochemical test positivity (FIT+) would be required. Considering thermal liquid biopsy (TLB) as a potential secondary test, the aim of this work was to study possible interferences of colonoscopy bowel preparation on TLB outcome on a retrospective study; (2) Methods: Three groups were studied: 1/514 FIT(+) patients enrolled in a colorectal screening program (CN and CP with normal and pathological colonoscopy, respectively), with blood samples obtained just before colonoscopy and after bowel preparation; 2/55 patients from the CN group with blood sample redrawn after only standard 8–10 h fasting and no bowel preparation (CNR); and 3/55 blood donors from the biobank considered as a healthy control group; (3) Results: The results showed that from the 514 patients undergoing colonoscopy, 247 had CN and 267 had CP. TLB parameters in these two groups were similar but different from those of the blood donors. The resampled patients (with normal colonoscopy and no bowel preparation) had similar TLB parameters to those of the blood donors. TLB parameters together with fluorescence spectra and other serum indicators (albumin and C-reactive protein) confirmed the statistically significant differences between normal colonoscopy patients with and without bowel preparation; (4) Conclusions: Bowel preparation seemed to alter serum protein levels and altered TLB parameters (different from a healthy subject). The diagnostic capability of other liquid-biopsy-based methods might also be compromised. Blood extraction after bowel preparation for colonoscopy should be avoided.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Fluorescence Liquid Biopsy for Cancer Detection Is Improved by Using Cationic Dendronized Hyperbranched Polymer

  • Morcuende-Ventura, Violeta
  • Hermoso-Durán, Sonia
  • Abian-Franco, Natalia
  • Pazo-Cid, Roberto
  • Ojeda, Jorge L.
  • Vega, Sonia
  • Sanchez-Gracia, Oscar
  • Velazquez-Campoy, Adrian
  • Sierra, Teresa
  • Abian, Olga
(1) Background: Biophysical techniques applied to serum samples characterization could promote the development of new diagnostic tools. Fluorescence spectroscopy has been previously applied to biological samples from cancer patients and differences from healthy individuals were observed. Dendronized hyperbranched polymers (DHP) based on bis(hydroxymethyl)propionic acid (bis-MPA) were developed in our group and their potential biomedical applications explored. (2) Methods: A total of 94 serum samples from diagnosed cancer patients and healthy individuals were studied (20 pancreatic ductal adenocarcinoma, 25 blood donor, 24 ovarian cancer, and 25 benign ovarian cyst samples). (3) Results: Fluorescence spectra of serum samples (fluorescence liquid biopsy, FLB) in the presence and the absence of DHP-bMPA were recorded and two parameters from the signal curves obtained. A secondary parameter, the fluorescence spectrum score (FSscore), was calculated, and the diagnostic model assessed. For pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer, the classification performance was improved when including DHP-bMPA, achieving high values of statistical sensitivity and specificity (over 85% for both pathologies). (4) Conclusions: We have applied FLB as a quick, simple, and minimally invasive promising technique in cancer diagnosis. The classification performance of the diagnostic method was further improved by using DHP-bMPA, which interacted differentially with serum samples from healthy and diseased subjects. These preliminary results set the basis for a larger study and move FLB closer to its clinical application, providing useful information for the oncologist during patient diagnosis.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Thermal Liquid Biopsy (TLB) of Blood Plasma as a Potential Tool to Help in the Early Diagnosis of Multiple Sclerosis

  • Annesi, Ferdinanda
  • Hermoso-Durán, Sonia
  • Rizzuti, Bruno
  • Bruno, Rosalinda
  • Pirritano, Domenico
  • Petrone, Alfredo
  • Del Giudice, Francesco
  • Ojeda, Jorge
  • Vega, Sonia
  • Sanchez-Gracia, Oscar
  • Velazquez-Campoy, Adrian
  • Abian, Olga
  • Guzzi, Rita
Background: Multiple sclerosis (MS) is frequently characterized by a variety of clinical signs, often exhibiting little specificity. The diagnosis requires a combination of medical observations and instrumental tests, and any support for its objective assessment is helpful. Objective: Herein, we describe the application of thermal liquid biopsy (TLB) of blood plasma samples, a methodology for predicting the occurrence of MS with a noninvasive, quick blood test. Methods: TLB allows one to define an index (TLB score), which provides information about overall real-time alterations in plasma proteome that may be indicative of MS. Results: This pilot study, based on 85 subjects (45 MS patients and 40 controls), showed good performance indexes (sensitivity and specificity both around 70%). The diagnostic methods better discriminate between early stage and low-burden MS patients, and it is not influenced by gender, age, or assumption of therapeutic drugs. TLB is more accurate for patients having low disability level (\u2264 3.0, measured by the expanded disability status scale, EDSS) and a relapsing-remitting diagnosis. Conclusion: Our results suggest that TLB can be applied to MS, especially in an initial phase of the disease when diagnosis is difficult and yet more important (in such cases, accuracy of prediction is close to 80%), as well as in personalized patient periodic monitoring. The next step will be determining its utility in differentiating between MS and other disorders, in particular in inflammatory diseases.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Serum-Based Detection of Pancreatic and Ovarian Cancer via a Nanoparticle-Enhanced Fluorescence Array and Machine Learning

  • Morcuende-Ventura, Violeta
  • Sánchez-Gracia, Oscar
  • Abian-Franco, Natalia
  • Jiménez-Pardo, Isabel
  • Herrer, Lucía
  • Castillo-Vallés, Martín
  • Lancelot, Alexandre
  • Falcó-Martí, F. Javier
  • Hermoso-Durán, Sonia
  • Pazo-Cid, Roberto
  • Lanas, Ángel
  • Velazquez-Campoy, Adrián
  • Sierra, Teresa
  • Abian, Olga
Early detection of oncological diseases such as pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OV) is pivotal for successful treatment but remains a significant challenge due to the lack of sensitive and specific diagnostic tests. Fluorescence spectroscopy, enhanced by the interaction of serum proteins with nanoparticles (NPs) based on linear–dendritic block copolymers, has emerged as a promising technique for the noninvasive detection of these malignancies. This study introduces a novel array-based assay methodology to evaluate the diagnostic capabilities of various NPs within serum samples using fluorescence. Methods: We synthesized three types of NPs (1-SH, 2-OH, 3-NH3+) and analyzed their fluorescence spectra in serum samples from patients with PDAC, OV, and control subjects. The samples were excited at 330 and 350 nm wavelengths to obtain their fluorescence emission spectra. An array of machine learning algorithms was applied, including boosting and tree-based methods, to assess the ability of the spectral data to discriminate between pathological and nonpathological states. The algorithms’ performance was measured by the area under the receiver operating characteristic curves (AUC). Results: The fluorescence spectra revealed distinct patterns for PDAC and OV pathologies. 3-NH3+ NPs exhibited the highest differential capacity with AUCs exceeding 80% for PDAC across all algorithms, except one. 2-OH NPs showed a strong discriminatory ability for OV with AUCs over 70%, utilizing all but one of the algorithms. 1-SH NPs, however, did not significantly increase differentiability. Boosting algorithms generally outperformed other methods, indicating their suitability for this diagnostic approach. Conclusions: The proposed assay array methodology enables the systematic evaluation of NPs’ diagnostic potential using fluorescence spectroscopy. The differential interactions between NPs and serum proteins specific to PDAC and OV highlight the method’s capability to discern pathological states. These findings suggest a path forward for developing NP-assisted fluorescence spectroscopy as a viable tool for cancer diagnostics, potentially leading to earlier detection and improved patient outcomes.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Integrating thermal liquid biopsy, clinical data, and mass spectrometry for early diagnosis and biomarker discovery in colorectal cancer

  • Hermoso-Durán, Sonia
  • Ortega-Alarcón, David
  • Johansen, Astrid Z.
  • McKay, Mattew J.
  • Johansen, Julia S.
  • Vega, Sonia
  • Feltoft, Claus L.
  • Dolin, Troels Gammeltoft
  • Lykke, Jakob
  • Fraunhoffer, Nicolas
  • Sánchez-Gracia, Oscar
  • Garrido, Pablo F.
  • Lanas, Ángel
  • Molloy, Mark P.
  • Velázquez-Campoy, Adrian
  • Abian, Olga
Early detection of colorectal cancer is essential to improving survival, where yet current diagnostic tools show limited performance. This study aimed to enhance diagnostic accuracy by integrating clinical variables with thermogram profiles obtained through serum-based thermal liquid biopsy and analyzed using machine learning models. We evaluated 328 patients with colorectal cancer and 355 symptomatic individuals with non-organ-specific cancer signs but negative diagnostic evaluations, to reproduce clinically relevant decision settings. The combined model showed improved classification performance compared with the use of clinical variables alone, particularly in patients with early-stage disease. In addition, proteomic analysis of samples stratified by thermogram patterns identified proteins associated with survival, including fibrinogen-like protein 1, supporting the biological relevance of these thermodynamic profiles. Together, these findings indicate that integrating serum thermogram information with routine clinical data can modestly strengthen diagnostic assessment and help identify biologically meaningful patient subgroups, offering a promising non-invasive colorectal
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

  • Neeb, Antje
  • Herranz Martín, Nicolás
  • Arce-Gallego, Sara
  • Buroni, Lorenzo
  • Athie Cuervo, Alejandro
  • Casanova Salas, Irene
  • González Rodríguez, Macarena
  • Morales Barrera, Rafael
  • Suárez Rodríguez, Cristina
  • Carles Galceran, Joan
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Miranda, Susana
  • Cordoba, Sarai
  • Castro, Natalia
  • Yuan, Wei
  • Casals, Teresa
Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata, Inhibición de ATR; Respuesta al daño del ADN; Cancer de prostata, ATR inhibition; DNA damage response; Prostate cancer, Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. Objective To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset. Design, setting, and participants We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell line models modified using CRISPR-Cas9 to impair ATM function were generated and used in drug-sensitivity and functional assays, with validation in a patient-derived model. Outcome measurements and statistical analysis ATM expression by IHC was correlated with clinical outcome using Kaplan-Meier curves and log-rank test; sensitivity to different drug combinations was assessed in the preclinical models. Results and limitations Overall, we detected ATM IHC loss in 68/631 (11%) PC patients in at least one biopsy, with synchronous and metachronous intrapatient heterogeneity; 46/71 (65%) biopsies with ATM loss had ATM mutations or deletions by NGS. ATM IHC loss was not associated with worse outcome from advanced disease, but ATM loss was associated with increased genomic instability (NtAI:number of subchromosomal regions with allelic imbalance extending to the telomere, p = 0.005; large-scale transitions, p = 0.05). In vitro, ATM loss PC models were sensitive to ATR inhibition, but had variable sensitivity to PARP inhibition; superior antitumour activity was seen with combined PARP and ATR inhibition in these models. Conclusions ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition., We gratefully acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence ( CEO13_2-002 ), the Prostate Cancer Foundation (including Young Investigator Awards to Joaquin Mateo, Pasquale Rescigno, and Adam Sharp), Stand Up To Cancer, and the UK Department of Health through an Experimental Cancer Medicine Centre grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Part of this work was also funded by a Deparment of Defense CDMRP Impact Award (W81XWH-18-1-0756) to Joaquin Mateo and by Instituto de Salud Carlos III through Grant FI19/00280 to Sara Arce-Gallego, Grant CP19/00170 to Nicolás Herranz, and Grant PI18/01384 to Joaquin Mateo. The authors affiliated to VHIO acknowledge the “la Caixa” Foundation ( ID 100010434 ) for funding under agreement LCF/PR/PR17/51120011 and funding from Fundacion FERO and Moventia . This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 837900 . The funding organisations had no role in the design, conduction or data analysis of this project, neither in the manuscript preparation.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Microbiological factors and patient-reported outcomes of exacerbation burden in Pseudomonas aeruginosa-colonised bronchiectasis: A one-year prospective study

  • Bueno Freire, Leticia
  • Oscanoa Huamán, Patricia Elena
  • Lopez-Aladid, Ruben
  • Alcaraz-Serrano, Victoria
  • Vázquez, Nil
  • Cabrera, Roberto
  • Gabarrús, Albert
  • Ceccato, Adrian
  • Ferrer, Miguel
  • Soler, Néstor
  • Torres, Antoni
  • Fernandez Barat, Laia
Background: Exacerbations are key determinants of disease progression and impaired health-related quality of life (HRQoL) in non-cystic fibrosis bronchiectasis (BE). Despite the recognised association between Pseudomonas aeruginosa (PA) and worse outcomes, factors driving exacerbation burden remain poorly characterised. In patients with PA-colonised BE, we aimed to assess whether microbiological factors, including colonisation status and PA phenotype, together with HRQoL domains and respiratory symptoms, were associated with time to first exacerbation, exacerbation severity, and post-exacerbation changes in HRQoL. Materials and Methods: This prospective longitudinal study followed PA-colonised BE adults for 12 months with quarterly stable-state assessments focussing on time and severity of first exacerbation. HRQoL was measured by the Quality of Life Questionnaire-Bronchiectasis (QOL-B). Multivariable Cox, Firth penalised logistic, and ANCOVA models were fitted in R. Results: A total of 68 patients were included. During follow-up, 52 patients (76.5%) experienced ≥1 exacerbation, including 14 (26.9%) whose first event required hospitalisation. Neither colonisation status nor PA phenotype were associated with exacerbation risk or hospitalisation. Better daytime cough (HR 0.63, 95%CI 0.41–0.97; p = 0.036) and dyspnoea while talking (HR 0.47, 95%CI 0.26–0.87; p = 0.016) were independently associated with lower exacerbation risk. Lower exertional dyspnoea burden (OR 0.29, 95%CI 0.10–0.67; p = 0.003) and lower sputum quantity (OR 0.46, 95%CI 0.19–0.93; p = 0.030) were associated with lower odds of hospitalisation, together with poorer Vitality, Social Functioning, and Health Perceptions. After exacerbation, Social Functioning declined significantly (Δ −7.50 points, 95%CI −14.87 to −0.14; p = 0.046) and mucoid PA was independently associated with worse Emotional Functioning (β −15.64, 95%CI −27.89 to −3.39; p = 0.013). Conclusions: In PA-colonised BE, selected respiratory symptoms and HRQoL domains were associated with exacerbation burden, whereas microbiological characteristics showed no clear associations with exacerbation risk or hospitalisation, supporting the incorporation of patient-reported outcomes into longitudinal assessment., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence

  • Arce Gallego, Sara
  • Romero-Lozano, Paula
  • Mir Arnau, Gisela
  • Aguilar, Daniel
  • Mast, Richard
  • Cresta Morgado, Pablo
  • Delgado-Serrano, Luisa
  • Simonetti, Sara
  • Macarena, Gonzalez
  • Marmolejo Castañeda, David Humberto
  • Morales-Barrera, Rafael
  • Semidey Raven, Maria Eugenia
  • Cordoba, Sarai
  • de Albert de Delás-Vigo, Matias
  • Planas, Jacques
  • Cuadras Solé, Mercè
  • Maldonado, Xavier
  • Casanova-Salas, Irene
  • Mas Malavila, Alba
  • Nonell, Lara
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • Vivancos, Ana
  • Llop-Guevara, Alba
  • Mateo, Joaquin
  • Carles, Joan
  • Suárez, Cristina
  • Serra, Violeta
Genomics; Immunofluorescence; Prostate cancer, Genòmica; Immunofluorescència; Càncer de pròstata, Genómica; Inmunofluorescencia; Cáncer de próstata, Metastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine clinical implementation of next-generation sequencing (NGS) is still limited. We investigated the association between genomic and functional loss of HRR, using NGS and RAD51 immunofluorescence (RAD51-IF) in 219 primary or metastatic biopsies from 187 patients with stage IV prostate cancer. NGS showed frequent genomic alterations in TP53 (40%), AR (15%), PTEN (14%), FOXA1 (12%), MYC (10%), BRCA2 (9%), ATM (8%), and BRCA1 (2%). We pursued RAD51-IF in 206 samples; of those, 139/206 (67%) were evaluable. 21% of samples had RAD51-low score compatible with HRR deficiency (HRD). RAD51-IF showed high sensitivity (71%) and specificity (86%) for BRCA1/2 alterations. Patients with RAD51-low scores experienced longer progression-free survival (PFS) on poly(ADP-ribose) polymerase inhibitors (PARPi) or platinum chemotherapy. RAD51-IF is feasible in routine clinical samples from patients with mPC and is associated with clinically relevant HRR gene alterations., This work was funded by an Impact Award from the Department of Defense CDMRP (PC170510P1) and a grant from AstraZeneca (ESR-21-21360). The funders had no role in the design or conduction of the study and were not involved in the analysis or interpretation of results. CRIS Cancer Foundation (grant TCL_2020-10) and Fundación AECC (LABAE20019MATE) and a Department of Defense Physician Science Award to J.M. (PC220307). S.A.-G. was supported by Instituto de Salud Carlos III (FI19/00280). P.C.M. was supported by an ESMO Translational Research Fellowship, funded by BMS (any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or BMS). I.C.-S. was supported by a Prostate Cancer Foundation YIA (24YOU12). A.L.-G. was supported by an AECC grant (INVES20095LLOP), and V.S. received funding from an ERA PerMed grant (ERAPERMED2019-215). The VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for its financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support of this research.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer

  • Arce Gallego, Sara
  • Esquefa, Victor
  • Domènech Garcia, Heura
  • Aguilar Villalba, Daniel
  • Casals, Teresa
  • Oliveira Tercero, Anna
  • de Llobet Cucalón, Lara
  • Anselmino, Nicolás
  • Herranz, Nicolas
  • Salca, Andrei
  • Mir Arnau, Gisela
  • Simonetti, Sara
  • Brandariz, Julian
  • Casanova-Salas, Irene
  • Mateo, Joaquin
  • Serra, Violeta
Combination therapy; PARPi inhibitors; Prostate cancer, Teràpia combinada; Inhibidors de PARPi; Càncer de pròstata, Terapia combinada; inhibidores de PARPi; Cáncer de próstata, PARP inhibitors (PARPi) are approved treatments for patients with metastatic prostate cancer (mPC); tumors with homologous recombination repair (HRR) defects are particularly sensitive to this drug class. While previous work has associated ATM defects with response to PARPi, its predictive value remains controversial and the mechanisms underlying sensitivity and eventual acquired drug resistance in this setting remain unclear. To address this, we generated in vitro prostate cancer models of acquired PARPi resistance to olaparib and saruparib, a novel selective PARP1 inhibitor and pursued functional characterization and drug sensitivity studies. We found that resistant models bypass the G2/M arrest induced by PARPi in sensitive models; and display a greater reliance on the ATR-dependent response to DNA damage and replication stress, mainly through the ATR-CHK1 axis. Consistently, we demonstrate in vivo that the combination of PARPi-ATRi in resistant models restores treatment sensitivity through enhancing replication stress. Collectively, these findings highlight an interplay between ATM-ATR signaling as a key mediator of PARPi sensitivity in ATM-deficient mPC and identify a promising therapeutic combination to prolong treatment response and potentially improve patients’ outcomes., This work was supported by funding from the CRIS Cancer Foundation (grant TCL_2020-10 to J. Mateo) and Fundación AECC (LABAE20019MATE), as well as a grant from the AstraZeneca Partners of Choice program (POC5270-10045025). Sara Arce-Gallego was supported by Instituto de Salud Carlos III (FI19/00280); Irene Casanova-Salas was supported by a Prostate Cancer Foundation YIA (24YOU12); Violeta Serra received funding from an ERA PerMed grant (ERAPERMED2019-215). We also acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for the financial support to VHIO as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Program from the Generalitat de Catalunya for their support on this research. We also would like to acknowledge Dr Lara Nonell and the Bioinformatics Unit at VHIO for their support in NGS analysis and Dr Tian Tian at VHIO for providing the SceI-BFP conjugated enzyme.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

  • Carreira, Suzanne
  • Porta, Nuria
  • Arce-Gallego, Sara
  • Llop Guevara, Alba
  • Bianchini, Diletta
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Seed, George
Pròstata; PARP; Biomarcadors, Próstata; PARP; Biomarcadores, Prostate; PARP; biomarkers, PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion. Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alteration while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit., TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020–21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno-Mingorance, Albert
  • Mir Cros, Alba
  • Goterris Bonet, Lidia
  • Rodríguez Garrido, Virginia
  • Sulleiro, Elena
  • Barberà Gracia, Mª Jesús
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca, Josep
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • VIÑADO, BELEN
  • Larrosa, María Nieves
  • Hoyos Mallecot, Yannick
Antimicrobial resistance; Shigella sonnei; Sexually transmitted infection, Resistencia antimicrobiana; Shigella sonnei; Infección de transmisión sexual, Resistència antimicrobiana; Shigella sonnei; Infecció de transmissió sexual, Background Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. Objectives To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. Results From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. Conclusions We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens., This work was partially supported by the ‘Ministerio de Economía y Competitividad’, ‘Instituto de Salud Carlos III’, and co-financed by the European Regional Development Fund (ERDF) ‘A Way to Achieve Europe’ (Spanish Network for Research in Infectious Diseases, grant number RD16/0016/0003) and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas, grant no. CB21/13/00054). A.M.M. is supported by a grant from the ‘Fondo de Investigación Sanitaria’ (Contratos Predoctorales de Formación en Investigación, grant number FI19/00315).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of next-generation sequencing (NGS) and next-generation flow (NGF) for minimal residual disease (MRD) assessment in multiple myeloma

  • Medina, Alejandro|||0000-0001-5609-2969
  • Puig, Noemí|||0000-0001-7535-3861
  • Flores-Montero, Juan|||0000-0002-1119-4387
  • Jimenez, Cristina
  • Sarasquete, M. Eugenia|||0000-0001-7335-3657
  • García-Álvarez, María|||0000-0001-8864-1168
  • Prieto-Conde, Isabel|||0000-0002-2510-8355
  • Chillon, Carmen
  • Alcoceba, Miguel|||0000-0002-3819-4846
  • Gutierrez, Norma C.
  • Oriol, Albert|||0000-0001-6804-2221
  • Rosinol, Laura
  • Bladé Creixenti, Juan|||0000-0002-4563-3405
  • Gironella, Mercedes|||0000-0002-8106-8909
  • Hernandez, Miguel T.
  • Gonzalez-Calle, Verónica
  • Cedena, María Teresa|||0000-0001-5851-3720
  • Paiva, Bruno|||0000-0003-1977-3815
  • San Miguel, Jesús|||0000-0002-9183-4857
  • Lahuerta, J. J.|||0000-0002-3393-9570
  • Mateos, M. V.|||0000-0003-2390-1218
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Orfao, Alberto|||0000-0002-0007-7230
  • González, Marcos
  • García-Sanz, Ramón|||0000-0003-4120-2787
Detecting persistent minimal residual disease (MRD) allows the identification of patients with an increased risk of relapse and death. In this study, we have evaluated MRD 3 months after transplantation in 106 myeloma patients using a commercial next-generation sequencing (NGS) strategy (LymphoTrack®), and compared the results with next-generation flow (NGF, EuroFlow). The use of different marrow pulls and the need of concentrating samples for NGS biased the applicability for MRD evaluation and favored NGF. Despite that, correlation between NGS and NGF was high (R = 0.905). The 3-year progression-free survival (PFS) rates by NGS and NGF were longer for undetectable vs. positive patients (NGS: 88.7% vs. 56.6%; NGF: 91.4% vs. 50%; p < 0.001 for both comparisons), which resulted in a 3-year overall survival (OS) advantage (NGS: 96.2% vs. 77.3%; NGF: 96.6% vs. 74.9%, p < 0.01 for both comparisons). In the Cox regression model, NGS and NGF negativity had similar results but favoring the latter in PFS (HR: 0.20, 95% CI: 0.09-0.45, p < 0.001) and OS (HR: 0.21, 95% CI: 0.06-0.75, p = 0.02). All these results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

The neurobiological basis of cognitive side effects of electroconvulsive therapy, a systematic review

  • Bassa, Adriana
  • Sagués, Teresa
  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Serra, Pilar
  • Martínez Amorós, Erika|||0000-0002-6718-7346
  • Palao, Diego|||0000-0002-3323-6568
  • Cano, Marta|||0000-0003-0675-9483
  • Cardoner, Narcís|||0000-0001-9633-0888
Decades of research have consistently demonstrated the efficacy of electroconvulsive therapy (ECT) for the treatment of major depressive disorder (MDD), but its clinical use remains somewhat restricted because of its cognitive side effects. The aim of this systematic review is to comprehensively summarize current evidence assessing potential biomarkers of ECT-related cognitive side effects. Based on our systematic search of human studies indexed in PubMed, Scopus, and Web of Knowledge, a total of 29 studies evaluating patients with MDD undergoing ECT were reviewed. Molecular biomarkers studies did not consistently identify concentration changes in plasma S-100 protein, neuron-specific enolase (NSE), or Aβ peptides significantly associated with cognitive performance after ECT. Importantly, these findings suggest that ECT-related cognitive side effects cannot be explained by mechanisms of neural cell damage. Notwithstanding, S-100b protein and Aβ40 peptide concentrations, as well as brain-derived neurotrophic factor (BDNF) polymorphisms, have been suggested as potential predictive biomarkers of cognitive dysfunction after ECT. In addition, recent advances in brain imaging have allowed us to identify ECT-induced volumetric and functional changes in several brain structures closely related to memory performance such as the hippocampus. We provide a preliminary framework to further evaluate neurobiological cognitive vulnerability profiles of patients with MDD treated with ECT.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Histone Modifications and Their Targeting in Lymphoid Malignancies

  • Fernández-Serrano, Miranda|||0000-0001-9040-8496
  • Winkler, René|||0000-0002-7570-0242
  • Santos, Juliana|||0000-0003-4148-9570
  • Le Pannérer, Marguerite Marie|||0000-0002-5779-8805
  • Buschbeck, Marcus|||0000-0002-3218-4567
  • Roué, Gaël|||0000-0003-0245-2257
In a wide range of lymphoid neoplasms, the process of malignant transformation is associated with somatic mutations in B cells that affect the epigenetic machinery. Consequential alterations in histone modifications contribute to disease-specific changes in the transcriptional program. Affected genes commonly play important roles in cell cycle regulation, apoptosis-inducing signal transduction, and DNA damage response, thus facilitating the emergence of malignant traits that impair immune surveillance and favor the emergence of different B-cell lymphoma subtypes. In the last two decades, the field has made a major effort to develop therapies that target these epigenetic alterations. In this review, we discuss which epigenetic alterations occur in B-cell non-Hodgkin lymphoma. Furthermore, we aim to present in a close to comprehensive manner the current state-of-the-art in the preclinical and clinical development of epigenetic drugs. We focus on therapeutic strategies interfering with histone methylation and acetylation as these are most advanced in being deployed from the bench-to-bedside and have the greatest potential to improve the prognosis of lymphoma patients.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

  • Corominas Argente del Castillo, Josep|||0000-0002-5351-9469
  • Sapena, Victor|||0000-0003-4379-6486
  • Sanduzzi Zamparelli, Marco|||0000-0003-3795-3705
  • Millán, Cristina
  • Samper, Esther
  • Llarch, Neus|||0000-0003-3209-0453
  • Iserte, Gemma|||0000-0003-3908-8743
  • Torres, Ferran|||0000-0002-7355-7913
  • Da Fonseca, Leonardo G.|||0000-0002-0216-3618
  • Muñoz-Martínez, S|||0000-0003-0663-0575
  • Forner, Alejandro|||0000-0002-9014-4950
  • Bruix, Jordi|||0000-0002-9826-0753
  • Boix, Loreto|||0000-0002-6015-3901
  • Reig, María|||0000-0002-5711-9534
Hepatocellular carcinoma is the second cause of cancer-related death worldwide. Of those advanced-stage patients who are treated with sorafenib, those who develop early dermatologic adverse events have a better prognosis. These events are possibly immune-related. Therefore, we analyzed the phenotype of 52 sorafenib-treated patients' circulating lymphocytes throughout treatment. We found that different co-stimulatory and immune exhaustion markers, such as Programmed cell death protein 1 (PD-1) and DNAX accessory molecule 1 (DNAM-1) amongst others, correlate with the probability of developing these adverse events, both before and during the treatment. We also compared the phenotype of those lymphocytes expressing DNAM-1 with those that do not, and while NK DNAM-1-expressing cells have a co-stimulatory phenotype, T DNAM-1-expressing cells are immune-suppressors. Overall, we set a rationale for the combination of sorafenib and immune-targeted therapies; and for the use of immune markers (such as DNAM-1) for patients' prognosis evaluation. Advanced hepatocellular carcinoma patients treated with sorafenib who develop early dermatologic adverse events (eDAEs) have a better prognosis. This may be linked to immune mechanisms, and thus, it is relevant to assess the association between peripheral immunity and the probability of developing eDAEs. Peripheral blood mononuclear cells of 52 HCC patients treated with sorafenib were analyzed at baseline and throughout the first eight weeks of therapy. T, B, Natural Killer cells, and their immune checkpoints expression data were characterized by flow cytometry. Cytokine release and immune-suppression assays were carried out ex vivo. Cox baseline and time-dependent regression models were applied to evaluate the probability of increased risk of eDAEs. DNAM-1, PD-1, CD69, and LAG-3 in T cells, plus CD16 and LAG-3 in NK cells, are significantly associated with the probability of developing eDAEs. While NK DNAM-1 + cells express activation markers, T DNAM-1 + cells induce immune suppression and show immune exhaustion. This is the first study to report an association between immune checkpoints expression in circulating immune cells and the increased incidence of eDAEs. Our results support the hypothesis for an off-target role of sorafenib in immune modulation. We also describe a novel association between DNAM-1 and immune exhaustion in T cells.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Spontaneous portosystemic shunts in liver cirrhosis, new approaches to an old problem

  • Vidal-González, Judit
  • Quiroga, Sergio|||0000-0001-8671-7616
  • Simón Talero, Macarena|||0000-0002-1409-3936
  • Genescà Ferrer, Joan|||0000-0002-0831-8422
Portal hypertension is the main consequence of liver cirrhosis, leading to severe complications such as variceal hemorrhage, ascites or hepatic encephalopathy. As an attempt to decompress the portal venous system, portal flow is derived into the systemic venous system through spontaneous portosystemic shunts (SPSSs), bypassing the liver. In this review, we aim to provide an overview of the published reports in relation to the prevalence and physiopathology behind the appearance of SPSS in liver cirrhosis, as well as the complications derived from its formation and its management. The role of SPSS embolization is specifically discussed, as SPSSs have been assessed as a therapeutic target, mainly for patients with recurrent/persistent hepatic encephalopathy and preserved liver function. Furthermore, different aspects of the role of SPSS in liver transplantation, as well as in candidates for transjugular intrahepatic portosystemic shunt are reviewed. In these settings, SPSS occlusion has been proposed to minimize possible deleterious effects, but results are so far inconclusive.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Assessing the benefits on quality of life of a multicomponent intervention for fibromyalgia syndrome in primary care, patients' and health professionals' appraisals: a qualitative study protocol

  • Arfuch, Victoria Mailen|||0000-0001-5935-6907
  • Caballol Angelats, Rosa|||0000-0001-5780-9888
  • Aguilar Martín, Carina|||0000-0002-2357-5726
  • Carrasco Querol, Noèlia|||0000-0002-5876-7082
  • Sancho Sol, Maria Cinta
  • González Serra, Gemma
  • Fusté Anguera, Immaculada|||0000-0002-1244-1108
  • Gonçalves, A. Q.|||0000-0003-3272-6861
  • Berenguera, Anna|||0000-0002-0889-2002
Fibromyalgia syndrome (FMS) is a complex condition still scarcely understood and with ambiguity when prescribing treatment. Both patients and healthcare providers can supply valuable information for the development of new treatment strategies. The qualitative narrative analysis of participant's accounts is potentially helpful to reveal new insights about their opinions, needs, and experiences and, consequently, to model healthcare interventions accurately. International treatment guidelines suggest a promising future for multicomponent intervention (MI) approaches for FMS. This study aims to assess the benefits of a MI for patients with FMS in the context of primary care (PC) in Terres de L'Ebre, Catalonia (Spain). Furthermore, it is intended to detect the overall perception of effectiveness and to understand patients' lived experience and its impact on the quality of life. Qualitative research from a socioconstructivism paradigm perspective and a Hermeneutic Phenomenological method. For data collection, four focus group discussions (FGDs) of 8-12 people (2 FGDs of patients and 2 of professionals) and 10-12 key informant interviews with the participants in the MI group will be carried out. All the information will be recorded and verbatim transcribed to perform an interpretive thematic analysis. This study protocol has been approved by the Clinical Research Ethics Committee from the IDIAPJGol Institute, on 25 April 2018 (code P18/068), according to the Declaration of Helsinki/Tokyo. All participants will receive oral/written information about the study, and they will be required to sign an informed consent sheet. Data anonymity will be guaranteed. Dissemination will be carried out through publications in scientific journals, presentations in academic meetings, workshops and through the local and national media. ClinicalTrials.gov: ; Pre-results.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

ICA1L Is Associated with Small Vessel Disease, A Proteome-Wide Association Study in Small Vessel Stroke and Intracerebral Haemorrhage

  • Cullell, Natalia|||0000-0001-5118-1014
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Molina, Jessica
  • Casas, Laura
  • Almeria, Marta|||0000-0001-7445-6113
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
  • Krupinski, Jerzy|||0000-0002-5136-8898
Small vessel strokes (SVS) and intracerebral haemorrhages (ICH) are acute outcomes of cerebral small vessel disease (SVD). Genetic studies combining both phenotypes have identified three loci associated with both traits. However, the genetic cis-regulation at the protein level associated with SVD has not been studied before. We performed a proteome-wide association study (PWAS) using FUSION to integrate a genome-wide association study (GWAS) and brain proteomic data to discover the common mechanisms regulating both SVS and ICH. Dorsolateral prefrontal cortex (dPFC) brain proteomes from the ROS/MAP study (N = 376 subjects and 1443 proteins) and the summary statistics for the SVS GWAS from the MEGASTROKE study (N = 237,511) and multi-trait analysis of GWAS (MTAG)-ICH-SVS from Chung et al. (N = 240,269) were selected. We performed PWAS and then a co-localization analysis with COLOC. The significant and nominal results were validated using a replication dPFC proteome (N = 152). The replicated results (q -value < 0.05) were further investigated for the causality relationship using summary data-based Mendelian randomization (SMR). One protein (ICA1L) was significantly associated with SVS (z-score = -4.42 and p -value = 9.6 × 10 -6) and non-lobar ICH (z-score = -4.8 and p -value = 1.58 × 10 -6) in the discovery PWAS, with a high co-localization posterior probability of 4. In the validation PWAS, ICA1L remained significantly associated with both traits. The SMR results for ICA1L indicated a causal association of protein expression levels in the brain with SVS (p -value = 3.66 × 10 -5) and non-lobar ICH (p -value = 1.81 × 10 -5). Our results show that the association of ICA1L with SVS and non-lobar ICH is conditioned by the cis-regulation of its protein levels in the brain.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Dating violence and associated factors among male and female adolescents in Spain

  • Vives-Cases, Carmen|||0000-0002-6797-5051
  • Pérez Martínez, Vanesa|||0000-0003-1811-0382
  • Davó-Blanes, MªCarmen|||0000-0001-7682-352X
  • Sánchez-SanSegundo, M.
  • Gil-González, D.
  • Abiétar, Daniel G.|||0000-0002-5268-3574
  • Sánchez-Martínez, Francesca|||0000-0001-8198-1661
  • Forcadell Díez, Lluís|||0000-0002-3934-4666
  • Pérez Albarracín, Glòria|||0000-0001-6653-3393
  • Sanz-Barbero, Belén|||0000-0001-6030-061X
Background Dating Violence (DV) is a public health problem that is on the rise. In this paper, we aim to analyse different factors associated with DV victimization among female and male adolescents in Spain, considering socioeconomic circumstances, sexual orientation and the presence of different attitudes and experiences related to violence. Methods Cross-sectional data from a convenience sample of 640 ever-partnered adolescents aged 13 to 17 at schools in the cities of Alicante (n = 359, 50.1% girls) and Terrassa (n = 281, 51.9%) in the context of an educational intervention to promote healthy relationships. We calculated the prevalence of different forms of DV (physical, sexual and control and fear) and carried out multivariate regression models by sex. Results 5.5% of girls and 8.7% of boys declared having suffered lifetime physical and/or sexual violence, while 22% of girls and 20.5% of boys reported control and/or fear victimization. The likelihood of DV was higher among migrants and those with foreign-born parents (aPR girls = 2.1 CI95%: 1.1-3.9; aPR boys = 1.9: CI95%: 1.0-3.6); prior experiences of abuse (aPR girls = 1.6; CI95%: 1.0-2.6; aPR boys = 1.7; CI95%: 1.1-2.6); and those who showed higher levels of machismo (aPR girls = 1.0; CI95%: 1.0-1.1; aPR boys = 1.0; CI95%: 1.0-1.1). In girls, DV increased among those who reported lesbian/bisexual orientation and poor relationship with teachers. Conclusions DV is socially patterned and increases among LGB adolescents (especially in the case of girls), migrants, and those with foreign-born parents, and adolescents who reported prior experiences of violence in childhood. Future DV prevention programs should consider social inequalities in the likelihood of DV and by reinforcing adolescents' abilities to recognize social support sources and reject machismo and violence.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The relationship between jumping to conclusions and social cognition in first-episode psychosis

  • Díaz-Cutraro, L.|||0000-0003-3985-2780
  • López-Carrilero, Raquel|||0000-0003-4110-794X
  • García-Mieres, Helena|||0000-0002-2813-1737
  • Ferrer-Quintero, Marta|||0000-0002-7935-9424
  • Verdaguer-Rodriguez, Marina
  • Barajas Vélez, Ana|||0000-0003-1103-9499
  • Grasa, Eva|||0000-0003-1100-7489
  • Pousa Tomàs, Esther|||0000-0003-4423-6739
  • Lorente Rovira, Esther
  • Barrigón, María Luisa|||0000-0002-2497-6353
  • Ruiz Delgado, Isabel
  • González-Higueras, Fermín|||0000-0002-0826-5981
  • Cid Colom, Jordi|||0000-0002-6406-0585
  • Mas-Expósito, Laia
  • Corripio, Iluminada|||0000-0003-2562-711X
  • Birulés, Irene|||0000-0001-6518-7310
  • Pélaez, Trinidad
  • Luengo, Ana
  • Beltran, Meritxell
  • Torres-Hernández, Pedro
  • Palma-Sevillano, Carolina|||0000-0001-5371-7417
  • Moritz, Steffen|||0000-0001-8601-0143
  • Garety, Philippa
  • Ochoa, Susana|||0000-0001-6792-1080
Jumping to conclusions (JTC) and impaired social cognition (SC) affect the decoding, processing, and use of social information by people with psychosis. However, the relationship between them had not been deeply explored within psychosis in general, and in first-episode psychosis (FEP) in particular. Our aim was to study the relationship between JTC and SC in a sample with FEP. We conducted a cross-sectional study with 121 patients with FEP, with measures to assess JTC (easy, hard, and salient probability tasks) and SC (emotional recognition, attributional style, and theory of mind). We performed Student's t-test and logistic regression in order to analyse these associations.We found a statistically significant and consistent relationship of small-moderate effect size between JTC (all three tasks) and impaired emotional recognition. Also, our results suggest a relationship between JTC and internal attributions for negative events. Relationships between JTC and theory of mind were not found. These results highlight the importance of psychological treatments oriented to work on a hasty reasoning style and on improving processing of social information linked to emotional recognition and single-cause attributions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Peripheral myeloid-derived suppressor cells are good biomarkers of the efficacy of fingolimod in multiple sclerosis

  • Camacho-Toledano, Celia
  • Machín-Díaz, Isabel
  • Calahorra, Leticia
  • Cabañas-Cotillas, María
  • Otaegui, David|||0000-0002-6625-5976
  • Castillo-Triviño, Tamara|||0000-0002-9249-3185
  • Villar, Luisa M.|||0000-0002-9067-3668
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Midaglia, Luciana|||0000-0001-7981-2228
  • García Domínguez, José Manuel
  • García-Arocha, Jennifer
  • Ortega, María Cristina
  • Clemente, Diego|||0000-0003-4829-9497
The increasing number of treatments that are now available to manage patients with multiple sclerosis (MS) highlights the need to develop biomarkers that can be used within the framework of individualized medicine. Fingolimod is a disease-modifying treatment that belongs to the sphingosine-1-phosphate receptor modulators. In addition to inhibiting T cell egress from lymph nodes, fingolimod promotes the immunosuppressive activity of myeloid-derived suppressor cells (MDSCs), whose monocytic subset (M-MDSCs) can be used as a biomarker of disease severity, as well as the degree of demyelination and extent of axonal damage in the experimental autoimmune encephalomyelitis (EAE) model of MS. In the present study, we have assessed whether the abundance of circulating M-MDSCs may represent a useful biomarker of fingolimod efficacy in EAE and in the clinical context of MS patients. Treatment with vehicle or fingolimod was orally administered to EAE mice for 14 days in an individualized manner, starting the day when each mouse began to develop clinical signs. Peripheral blood from EAE mice was collected previous to treatment and human peripheral blood mononuclear cells (PBMCs) were collected from fingolimod to treat MS patients' peripheral blood. In both cases, M-MDSCs abundance was analyzed by flow cytometry and its relationship with the future clinical affectation of each individual animal or patient was assessed. Fingolimod-treated animals presented a milder EAE course with less demyelination and axonal damage, although a few animals did not respond well to treatment and they invariably had fewer M-MDSCs prior to initiating the treatment. Remarkably, M-MDSC abundance was also found to be an important and specific parameter to distinguish EAE mice prone to better fingolimod efficacy. Finally, in a translational effort, M-MDSCs were quantified in MS patients at baseline and correlated with different clinical parameters after 12 months of fingolimod treatment. M-MDSCs at baseline were highly representative of a good therapeutic response to fingolimod, i.e., patients who met at least two of the criteria used to define non-evidence of disease activity-3 (NEDA-3) 12 months after treatment. Our data indicate that M-MDSCs might be a useful predictive biomarker of the response of MS patients to fingolimod. The online version contains supplementary material available at 10.1186/s12974-022-02635-3.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness

  • Sonzini, Giorgia
  • Granados-Aparici, Sofia
  • Sanegre, Sabina
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
  • Diaz-Martin, Juan
  • de Andrea, Carlos
  • Eritja, Núria
  • Bao Caamano, Aida
  • Costa-Fraga, Nicolás|||0000-0002-0869-8509
  • García-Ros, David
  • Salguero-Aranda, Carmen
  • Davidson, Ben
  • López-López, Rafael|||0000-0002-2240-6277
  • Melero, Ignacio|||0000-0002-1360-348X
  • Navarro, Samuel
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • De Álava, Enrique|||0000-0001-8400-046X
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Noguera, Rosa
The incidence of new cancer cases is expected to increase significantly in the future, posing a worldwide problem. In this regard, precision oncology and its diagnostic tools are essential for developing personalized cancer treatments. Digital pathology (DP) is a particularly key strategy to study the interactions of tumor cells and the tumor microenvironment (TME), which play a crucial role in tumor initiation, progression and metastasis. The purpose of this study was to integrate data on the digital patterns of reticulin fiber scaffolding and the immune cell infiltrate, transcriptomic and epigenetic profiles in aggressive uterine adenocarcinoma (uADC), uterine leiomyosarcoma (uLMS) and their respective lung metastases, with the aim of obtaining key TME biomarkers that can help improve metastatic prediction and shed light on potential therapeutic targets. Automatized algorithms were used to analyze reticulin fiber architecture and immune infiltration in colocalized regions of interest (ROIs) of 133 invasive tumor front (ITF), 89 tumor niches and 70 target tissues in a total of six paired samples of uADC and nine of uLMS. Microdissected tissue from the ITF was employed for transcriptomic and epigenetic studies in primary and metastatic tumors. Reticulin fiber scaffolding was characterized by a large and loose reticular fiber network in uADC, while dense bundles were found in uLMS. Notably, more similarities between reticulin fibers were observed in paired uLMS then paired uADCs. Transcriptomic and multiplex immunofluorescence-based immune profiling showed a higher abundance of T and B cells in primary tumor and in metastatic uADC than uLMS. Moreover, the epigenetic signature of paired samples in uADCs showed more differences than paired samples in uLMS. Some epigenetic variation was also found between the ITF of metastatic uADC and uLMS. Altogether, our data suggest a correlation between morphological and molecular changes at the ITF and the degree of aggressiveness. The use of DP tools for characterizing reticulin scaffolding and immune cell infiltration at the ITF in paired samples together with information provided by omics analyses in a large cohort will hopefully help validate novel biomarkers of tumor aggressiveness, develop new drugs and improve patient quality of life in a much more efficient way.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Apolipoprotein and lrp1-based peptides as new therapeutic tools in atherosclerosis

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Solanelles Curco, Angels
  • García Rodríguez, Jesús Eduardo|||0000-0002-7758-6789
  • Julve i Gil, Josep|||0000-0002-6531-2246
  • Rives Jimenez, Jose|||0009-0001-5725-9270
  • Benitez, Sonia|||0000-0003-3565-0743
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several antiatherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Rp11-362k2.2:Rp11-767i20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma. a gwas meta-analysis

  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Carrera, Caty|||0000-0002-0804-0969
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Castillo, J.
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Rodríguez-Castro, E.
  • Millán, M.
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • Bustamante, Alejandro|||0000-0003-4390-8900
  • López-Cancio, E.
  • Ribó, M.
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Giralt Steinhauer, Eva|||0000-0002-7463-0983
  • Soriano-Tárraga, C.
  • Vives-Bauza, C.
  • Diaz-Navarro, Rosa
  • Tur, Silvia
  • Obach, Víctor|||0000-0002-0518-1053
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Segura, T.
  • Serrano-Heras, G.
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Guisado-Alonso, Daniel|||0000-0002-5799-3184
  • Guasch Jiménez, Marina|||0000-0001-6024-8348
  • Marín-Bueno, Rebeca|||0000-0002-0354-6602
  • Martínez-Domeño, Alejandro|||0000-0002-9933-3192
  • Freijo-Guerrero, M.D.M.
  • Moniche, F.
  • Cabezas, Juan Antonio
  • Castellanos, M.
  • Krupinsky, J.
  • Strbian, D.
  • Tatlisumak, T.
  • Thijs, V.
  • Lemmens, R.
  • Slowik, Agnieszka
  • Pera, J.
  • Heitsch, Laura
  • Ibañez, Laura
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Dhar, R.
  • Lee, J.M.
  • Montaner, J.
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Stroke is one of the most common causes of death and disability. Reperfusion therapies are the only treatment available during the acute phase of stroke. Due to recent clinical trials, these therapies may increase their frequency of use by extending the time-window administration, which may lead to an increase in complications such as hemorrhagic transformation, with parenchymal hematoma (PH) being the more severe subtype, associated with higher mortality and disability rates. Our aim was to find genetic risk factors associated with PH, as that could provide molecular targets/pathways for their prevention/treatment and study its genetic correlations to find traits sharing genetic background. We performed a GWAS and meta-analysis, following standard quality controls and association analysis (fastGWAS), adjusting age, NIHSS, and principal components. FUMA was used to annotate, prioritize, visualize, and interpret the meta-analysis results. The total number of patients in the meta-analysis was 2034 (216 cases and 1818 controls). We found rs79770152 having a genome-wide significant association (beta 0.09, p-value 3.90 × 10) located in the RP11-362K2.2:RP11-767I20.1 gene and a suggestive variant (rs13297983: beta 0.07, p-value 6.10 × 10) located in PCSK5 associated with PH occurrence. The genetic correlation showed a shared genetic background of PH with Alzheimer's disease and white matter hyperintensities. In addition, genes containing the ten most significant associations have been related to aggregated amyloid-β, tau protein, white matter microstructure, inflammation, and matrix metalloproteinases.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA

  • Ruiz Bañobre, Juan|||0000-0003-0755-4295
  • Rodríguez Casanova, Aitor|||0000-0002-9828-3613
  • Costa-Fraga, Nicolás|||0000-0002-0869-8509
  • Bao Caamano, Aida
  • Álvarez Castro, Ana
  • Carreras Presas, Martín
  • Brozos Vázquez, Elena
  • Vidal Insua, Yolanda
  • Vázquez Rivera, Francisca
  • Candamio Folgar, Sonia|||0000-0003-4007-5990
  • Mosquera Presedo, Manuel|||0000-0002-9802-1082
  • Lago Lestón, Ramón M.|||0000-0002-1166-7754
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
  • Vázquez Bueno, José Ángel
  • Sanz Pamplona, Rebeca|||0000-0002-2187-3527
  • Moreno Aguado, Victor Raul|||0000-0002-2818-5487
  • Goel, Ajay|||0000-0003-1396-6341
  • Castillo, Lourdes
  • Martín, Ana C.
  • Arroyo, Rocío
  • Esteller, M.|||0000-0003-4490-6093
  • Crujeiras, Ana B.|||0000-0003-4392-0301
  • López López, Rafael|||0000-0003-1315-655X
  • Diaz-Lagares, Angel|||0000-0002-9114-9227
Background: Current noninvasive assays have limitations in the early detection of colorectal cancer. We evaluated the clinical utility of promoter methylation of the long noncoding RNA LINC00473 as a noninvasive biomarker to detect colorectal cancer and associated precancerous lesions. Methods: We evaluated the epigenetic regulation of LINC00473 through promoter hypermethylation in colorectal cancer cell lines using bisulfite genomic sequencing and expression analyses. DNA methylation of LINC00473 was analyzed in primary colorectal tumors using 450K arrays and RNA-seq from The Cancer Genome Atlas (TCGA). Tissue-based findings were validated in several independent cohorts of colorectal cancer and advanced colorectal polyp patients by pyrosequencing. We explored the clinical utility of LINC00473 methylation for the early detection of colorectal cancer in plasma cell-free DNA by quantitative methylation-specific PCR and droplet digital PCR. Results: LINC00473 showed transcriptionally silencing due to promoter hypermethylation in colorectal cancer cell lines and primary tumors. Methylation of the LINC00473 promoter accurately detected primary colorectal tumors in two independent clinical cohorts, with areas under the receiver operating characteristic curves (AUCs) of 0.94 and 0.89. This biomarker also identified advanced colorectal polyps from two other tissue-based clinical cohorts with high diagnostic accuracy (AUCs of 0.99 and 0.78). Finally, methylation analysis of the LINC00473 promoter in plasma cell-free DNA accurately identified patients with colorectal cancer and advanced colorectal polyps (AUCs of 0.88 and 0.84, respectively), which was confirmed in an independent cohort of patients. Conclusions: Hypermethylation of the LINC00473 promoter is a new promising biomarker for noninvasive early detection of colorectal cancer and related precancerous lesions.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of Differentially Expressed MicroRNAs in Serum and Lung Tissues from Individuals with Severe Asthma Treated with Oral Glucocorticoids

  • Gil-Martínez, Marta|||0000-0002-2075-7874
  • Lorente-Sorolla, Clara|||0000-0003-0404-9453
  • Rodrigo-Muñoz, José Manuel|||0000-0003-3873-4563
  • Lendínez, Miguel Ángel
  • Núñez-Moreno, Gonzalo|||0000-0001-5982-570X
  • de la Fuente, Lorena
  • Minguez, Pablo|||0000-0003-4099-9421
  • Mahíllo-Fernández, Ignacio|||0000-0003-0558-6541
  • Sastre, Joaquin|||0000-0003-4689-6837
  • Valverde-Monge, Marcela|||0000-0002-0172-3951
  • Quirce Gancedo, Santiago|||0000-0001-8086-0921
  • Caballero, María L.
  • González-Barcala, Francisco-Javier|||0000-0001-5847-4784
  • Arismendi, Ebymar|||0000-0002-7749-2838
  • Bobolea, Irina|||0000-0002-7425-2417
  • Valero, Antonio
  • Muñoz Gall, Francisco Javier|||0000-0002-8693-022X
  • Cruz, María Jesús|||0000-0001-9759-5466
  • Martínez Rivera, Carlos|||0000-0003-1031-2561
  • Plaza, Vicente|||0000-0003-2567-5496
  • Olaguibel, José M.
  • Del Pozo, Victoria|||0000-0001-6228-1969
Nowadays, microRNAs (miRNAs) are increasingly used as biomarkers due to their potential contribution to the diagnosis and targeted treatment of a range of diseases. The aim of the study was to analyze the miRNA expression profiles in serum and lung tissue from patients with severe asthma treated with oral corticosteroids (OCS) and those without OCS treatment. For this purpose, serum and lung tissue miRNAs of OCS and non-OCS asthmatic individuals were evaluated by miRNAs-Seq, and subsequently miRNA validation was performed using RT-qPCR. Additionally, pathway enrichment analysis of deregulated miRNAs was conducted. We observed altered expression by the next-generation sequencing (NGS) of 11 miRNAs in serum, of which five (hsa-miR-148b-3p, hsa-miR-221-5p, hsa-miR-618, hsa-miR-941, and hsa-miR-769-5p) were validated by RT-qPCR, and three miRNAs in lung tissue (hsa-miR-144-3p, hsa-miR-144-5p, and hsa-miR-451a). The best multivariate logistic regression model to differentiate individuals with severe asthma, treated and untreated with OCS, was to combine the serum miRNAs hsa-miR-221-5p and hsa-miR-769-5p. Expression of hsa-miR-148b-3p and hsa-miR-221-5p correlated with FEV/FVC (%) and these altered miRNAs act in key signaling pathways for asthma disease and the regulated expression of some genes (FOXO3, PTEN, and MAPK3) involved in these pathways. In conclusion, there are miRNA profiles differentially expressed in OCS-treated individuals with asthma and could be used as biomarkers of OCS treatment.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The interplay of mitochondrial oxidative stress and endoplasmic reticulum stress in cardiovascular fibrosis in obese rats

  • Souza-Neto, Francisco V.
  • Jiménez-González, Sara
  • Delgado-Valero, Beatriz
  • Jurado-López, Raquel|||0000-0002-9149-1073
  • Genty, Marie
  • Romero-Miranda, Ana
  • Rodríguez, Cristina|||0000-0002-6472-5647
  • Nieto, María Luisa
  • Martínez-Martínez, Ernesto
  • Cachofeiro, Victoria
We have evaluated the role of mitochondrial oxidative stress and its association with endoplasmic reticulum (ER) stress activation in the progression of obesity-related cardiovascular fibrosis. MitoQ (200 µM) was orally administered for 7 weeks to male Wistar rats that were fed a high-fat diet (HFD, 35% fat) or a control diet (CT, 3.5% fat). Obese animals presented cardiovascular fibrosis accompanied by increased levels of extracellular matrix proteins and profibrotic mediators. These alterations were associated with ER stress activation characterized by enhanced levels (in heart and aorta vs. CT group, respectively) of immunoglobulin binding protein (BiP; 2.1-and 2.6-fold, respectively), protein disulfide-isomerase A6 (PDIA6; 1.9-fold) and CCAAT-enhancer-binding homologous protein (CHOP; 1.5-and 1.8-fold, respectively). MitoQ treatment was able to prevent (p < 0.05) these modifications at cardiac and aortic levels. MitoQ (5 nM) and the ER stress inhibitor, 4-phenyl butyric acid (4 µM), were able to block the prooxidant and profibrotic effects of angiotensin II (Ang II, 10 M) in cardiac and vascular cells. Therefore, the data show a crosstalk between mitochondrial oxidative stress and ER stress activation, which mediates the development of cardiovascular fibrosis in the context of obesity and in which Ang II can play a relevant role.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Regional grey matter microstructural changes and volume loss according to disease duration in multiple sclerosis patients

  • Solana, Elisabeth|||0000-0001-7973-2439
  • Martinez-Heras, Eloy|||0000-0001-9937-3162
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Lopez-Soley, Elisabet
  • Radua, Joaquim|||0000-0003-1240-5438
  • Sola-Valls, Nuria
  • Montejo, Carmen
  • Blanco Morgado, Yolanda|||0000-0002-1834-0498
  • Pulido-Valdeolivas, Irene|||0000-0003-0188-2458
  • Sepúlveda, Maria
  • Andorra, Magí
  • Berenguer, Juan|||0000-0001-8541-8200
  • Villoslada, P.|||0000-0002-8735-6119
  • Martinez-Lapiscina, E.H.
  • Prados Carrasco, Ferran|||0000-0002-7872-0142
  • Saiz, Albert|||0000-0002-5793-8791
  • Fortea, Juan|||0000-0002-1340-638X
  • Llufriu, Sara|||0000-0003-4273-9121
The spatio-temporal characteristics of grey matter (GM) impairment in multiple sclerosis (MS) are poorly understood. We used a new surface-based diffusion MRI processing tool to investigate regional modifications of microstructure, and we quantified volume loss in GM in a cohort of patients with MS classified into three groups according to disease duration. Additionally, we investigated the relationship between GM changes with disease severity. We studied 54 healthy controls and 247 MS patients classified regarding disease duration: MS1 (less than 5 years, n = 67); MS2 (5-15 years, n = 107); and MS3 (more than15 years, n = 73). We compared GM mean diffusivity (MD), fractional anisotropy (FA) and volume between groups, and estimated their clinical associations. Regional modifications in diffusion measures (MD and FA) and volume did not overlap early in the disease, and became widespread in later phases. We found higher MD in MS1 group, mainly in the temporal cortex, and volume reduction in deep GM and left precuneus. Additional MD changes were evident in cingulate and occipital cortices in the MS2 group, coupled to volume reductions in deep GM and parietal and frontal poles. Changes in MD and volume extended to more than 80% of regions in MS3 group. Conversely, increments in FA, with very low effect size, were observed in the parietal cortex and thalamus in MS1 and MS2 groups, and extended to the frontal lobe in the later group. MD and GM changes were associated with white matter lesion load and with physical and cognitive disability. Microstructural integrity loss and atrophy present differential spatial predominance early in MS and accrual over time, probably due to distinct pathogenic mechanisms that underlie tissue damage.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A novel nfix-stat6 gene fusion in solitary fibrous tumor, A case report

  • Moura, David S.
  • Díaz-Martín, Juan|||0000-0002-3985-6434
  • Bagué Rosell, Sílvia|||0000-0001-9980-7231
  • Orellana Fernández, Ruth|||0000-0003-1260-7064
  • Sebio, Ana|||0000-0003-3333-2370
  • Mondaza Hernandez, Jose Lucinio|||0000-0002-5642-3796
  • Salguero-Aranda, Carmen
  • Rojo, Federico|||0000-0001-9989-0290
  • Hindi, Nadia|||0000-0002-5864-762X
  • Fletcher, Christopher D.M.
  • Martín Broto, Javier|||0000-0001-7350-6916
Solitary fibrous tumor is a rare subtype of soft-tissue sarcoma with a wide spectrum of histopathological features and clinical behaviors, ranging from mildly to highly aggressive tumors. The defining genetic driver alteration is the gene fusion NAB2-STAT6, resulting from a paracentric inversion within chromosome 12q, and involving several different exons in each gene. STAT6 (sig-nal transducer and activator of transcription 6) nuclear immunostaining and/or the identification of NAB2-STAT6 gene fusion is required for the diagnostic confirmation of solitary fibrous tumor. In the present study, a new gene fusion consisting of Nuclear Factor I X (NFIX), mapping to 19p13.2 and STAT6, mapping to 12q13.3 was identified by targeted RNA-Seq in a 74-year-old female patient diagnosed with a deep-seated solitary fibrous tumor in the pelvis. Histopathologically, the neo-plasm did not display nuclear pleomorphism or tumor necrosis and had a low proliferative index. A total of 378 unique reads spanning the NFIXexon8-STAT6exon2 breakpoint with 55 different start sites were detected in the bioinformatic analysis, which represented 59.5% of the reads intersecting the genomic location on either side of the breakpoint. Targeted RNA-Seq results were validated by RT-PCR/ Sanger sequencing. The identification of a new gene fusion partner for STAT6 in solitary fibrous tumor opens intriguing new hypotheses to refine the role of STAT6 in the sarcomatogenesis of this entity.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Kynurenine pathway in post-mortem prefrontal cortex and cerebellum in schizophrenia, relationship with monoamines and symptomatology

  • Afia, Amira Ben
  • Vila, Èlia|||0000-0003-2790-5400
  • Macdowell, Karina S.|||0000-0002-1527-8895
  • Ormazábal, Aida
  • Leza, Juan Carlos|||0000-0002-9901-0094
  • Haro Abad, Josep Maria|||0000-0002-3984-277X
  • Artuch, R.|||0000-0002-3422-9685
  • Ramos Josemaría, Belén|||0000-0002-4577-2106
  • Garcia-Bueno, Borja|||0000-0001-7320-1530
The cortico-cerebellar-thalamic-cortical circuit has been implicated in the emergence of psychotic symptoms in schizophrenia (SZ). The kynurenine pathway (KP) has been linked to alterations in glutamatergic and monoaminergic neurotransmission and to SZ symptomatology through the production of the metabolites quinolinic acid (QA) and kynurenic acid (KYNA). This work describes alterations in KP in the post-mortem prefrontal cortex (PFC) and cerebellum (CB) of 15 chronic SZ patients and 14 control subjects in PFC and 13 control subjects in CB using immunoblot for protein levels and ELISA for interleukins and QA and KYNA determinations. Monoamine metabolites were analysed by high-performance liquid chromatography and SZ symptomatology was assessed by Positive and Negative Syndrome Scale (PANSS). The association of KP with inflammatory mediators, monoamine metabolism and SZ symptomatology was explored. In the PFC, the presence of the anti-inflammatory cytokine IL-10 together with IDO2 and KATII enzymes decreased in SZ, while TDO and KMO enzyme expression increased. A network interaction analysis showed that in the PFC IL-10 was coupled to the QA branch of the kynurenine pathway (TDO-KMO-QA), whereas IL-10 associated with KMO in CB. KYNA in the CB inversely correlated with negative and general PANSS psychopathology. Although there were no changes in monoamine metabolite content in the PFC in SZ, a network interaction analysis showed associations between dopamine and methoxyhydroxyphenylglycol degradation metabolite. Direct correlations were found between general PANSS psychopathology and the serotonin degradation metabolite, 5-hydroxyindoleacetic acid. Interestingly, KYNA in the CB inversely correlated with 5-hydroxyindoleacetic acid in the PFC. Thus, this work found alterations in KP in two brain areas belonging to the cortico-cerebellar-thalamic-cortical circuit associated with SZ symptomatology, with a possible impact across areas in 5-HT degradation. The online version contains supplementary material available at 10.1186/s12974-021-02260-6.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells

  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Martínez Bosch, Neus|||0000-0003-3596-0039
  • Manero-Rupérez, Noemí
  • Claudi, Lene
  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Soler Castany, Marta
  • Ros-Blanco, Lia
  • Navarro, Pilar|||0000-0003-4314-4584
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
Dyslipidemia, metabolic disorders and/or obesity are postulated as risk factors for pancreatic ductal adenocarcinoma (PDAC). The majority of patients with these metabolic alterations have low density lipoproteins (LDLs) with increased susceptibility to become aggregated in the extracellular matrix (ECM). LDL aggregation can be efficiently inhibited by low-density lipoprotein receptor-related protein 1 (LRP1)-based peptides. The objectives of this work were: (i) to determine if aggregated LDLs affect the intracellular cholesteryl ester (CE)/free cholesterol (FC) ratio and/or the tumor pancreatic cell proliferation, using sphingomyelinase-modified LDL particles (Aggregated LDL, AgLDL); and (ii) to test whether LRP1-based peptides, highly efficient against LDL aggregation, can interfere in these processes. For this, we exposed human pancreatic cancer cell lines (PANC-1, RWP-1 and Capan-1) to native (nLDL) or AgLDLs in the absence or presence of LRP1-based peptides (DP3) or irrelevant peptides (IP321). Results of thin-layer chromatography (TLC) following lipid extraction indicate that AgLDLs induce a higher intracellular CE/FC ratio than nLDL, and that DP3 but not IP321 counteracts this effect. AgLDLs also increase PANC-1 cell proliferation, which is inhibited by the DP3 peptide. Our results indicate that AgLDL-induced intracellular CE accumulation plays a crucial role in the proliferation of pancreatic tumor cell lines. Peptides with anti-LDL aggregation properties may thus exhibit anti-tumor effects.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Polygenic Risk Score Based on a Cardioembolic Stroke Multitrait Analysis Improves a Clinical Prediction Model for This Stroke Subtype

  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cullell, Natalia|||0000-0001-5118-1014
  • Lledós, Miquel|||0000-0001-8832-789X
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Sobrino, Tomás|||0000-0002-9760-8690
  • Campos, Francisco|||0000-0001-8665-1039
  • Castillo, José
  • Freijo, Marimar
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Obach, Víctor|||0000-0002-0518-1053
  • Álvarez Sabín, José|||0000-0002-8054-9209
  • Molina, Carlos A.|||0000-0001-6058-6259
  • Ribo, Marc|||0000-0001-9242-043X
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Muñoz-Narbona, Lucia|||0000-0002-0884-3024
  • López-Cancio, Elena|||0000-0001-5757-9074
  • Millán Torné, Mònica|||0000-0002-4692-5936
  • Diaz-Navarro, Rosa
  • Vives-Bauza, Cristòfol
  • Serrano-Heras, Gemma|||0000-0001-9368-4832
  • Segura, Tomás|||0000-0003-3625-0987
  • Ibañez, Laura
  • Heitsch, Laura
  • Delgado, Pilar
  • Dhar, Rajat|||0000-0002-5167-5097
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Delgado Mederos, Raquel|||0000-0003-3737-7226
  • Prats Sánchez, Luis Antonio|||0000-0002-3192-4631
  • Camps-Renom, Pol|||0000-0001-6587-6271
  • Blay, Natalia|||0000-0002-7160-8529
  • Sumoy, Lauro|||0000-0003-0005-4618
  • de Cid, Rafael|||0000-0003-3579-6777
  • Montaner, Joan|||0000-0003-4845-2279
  • Cruchaga, Carlos|||0000-0002-0276-2899
  • Lee, Jim-Moo
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background: Occult atrial fibrillation (AF) is one of the major causes of embolic stroke of undetermined source (ESUS). Knowing the underlying etiology of an ESUS will reduce stroke recurrence and/or unnecessary use of anticoagulants. Understanding cardioembolic strokes (CES), whose main cause is AF, will provide tools to select patients who would benefit from anticoagulants among those with ESUS or AF. We aimed to discover novel loci associated with CES and create a polygenetic risk score (PRS) for a more efficient CES risk stratification. Methods: Multitrait analysis of GWAS (MTAG) was performed with MEGASTROKE-CES cohort (n = 362,661) and AF cohort (n = 1,030,836). We considered significant variants and replicated those variants with MTAG p-value < 5 × 10 influencing both traits (GWAS-pairwise) with a p-value < 0.05 in the original GWAS and in an independent cohort (n = 9,105). The PRS was created with PRSice-2 and evaluated in the independent cohort. Results: We found and replicated eleven loci associated with CES. Eight were novel loci. Seven of them had been previously associated with AF, namely, CAV1, ESR2, GORAB, IGF1R, NEURL1, WIPF1, and ZEB2. KIAA1755 locus had never been associated with CES/AF, leading its index variant to a missense change (R1045W). The PRS generated has been significantly associated with CES improving discrimination and patient reclassification of a model with age, sex, and hypertension. Conclusion: The loci found significantly associated with CES in the MTAG, together with the creation of a PRS that improves the predictive clinical models of CES, might help guide future clinical trials of anticoagulant therapy in patients with ESUS or AF.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Altered methylation pattern in EXOC4 is associated with stroke outcome, an epigenome-wide association study

  • Cullell, Natalia|||0000-0001-5118-1014
  • Soriano Tárraga, Carolina|||0000-0002-5635-273X
  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Muiño, Elena|||0000-0001-5839-7328
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Esteller, M.|||0000-0003-4490-6093
  • Castro de Moura, Manuel|||0000-0002-8488-5306
  • Montaner, Joan|||0000-0003-4845-2279
  • Rosell Novel, Anna|||0000-0003-1082-3599
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Martí-Fàbregas, Joan|||0000-0001-9229-8649
  • Krupinski, Jerzy|||0000-0002-5136-8898
  • Roquer González, Jaume|||0000-0001-5992-2606
  • Jimenez-Conde, Jordi|||0000-0002-2623-6199
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Background and purpose: The neurological course after stroke is highly variable and is determined by demographic, clinical and genetic factors. However, other heritable factors such as epigenetic DNA methylation could play a role in neurological changes after stroke. Methods: We performed a three-stage epigenome-wide association study to evaluate DNA methylation associated with the difference between the National Institutes of Health Stroke Scale (NIHSS) at baseline and at discharge (ΔNIHSS) in ischaemic stroke patients. DNA methylation data in the Discovery (n = 643) and Replication (n = 62) Cohorts were interrogated with the 450 K and EPIC BeadChip. Nominal CpG sites from the Discovery (p value < 10) were also evaluated in a meta-analysis of the Discovery and Replication cohorts, using a random-fixed effect model. Metabolic pathway enrichment was calculated with methylGSA. We integrated the methylation data with 1305 plasma protein expression levels measured by SOMAscan in 46 subjects and measured RNA expression with RT-PCR in a subgroup of 13 subjects. Specific cell-type methylation was assessed using EpiDISH. Results: The meta-analysis revealed an epigenome-wide significant association in EXOC4 (p value = 8.4 × 10) and in MERTK (p value = 1.56 × 10). Only the methylation in EXOC4 was also associated in the Discovery and in the Replication Cohorts (p value = 1.14 × 10 and p value = 1.3 × 10, respectively). EXOC4 methylation negatively correlated with the long-term outcome (coefficient = - 4.91) and showed a tendency towards a decrease in EXOC4 expression (rho = - 0.469, p value = 0.091). Pathway enrichment from the meta-analysis revealed significant associations related to the endocytosis and deubiquitination processes. Seventy-nine plasma proteins were differentially expressed in association with EXOC4 methylation. Pathway analysis of these proteins showed an enrichment in natural killer (NK) cell activation. The cell-type methylation analysis in blood also revealed a differential methylation in NK cells. Conclusions: DNA methylation of EXOC4 is associated with a worse neurological course after stroke. The results indicate a potential modulation of pathways involving endocytosis and NK cells regulation.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy

  • Ribeiro, Marcelo Lima
  • Profitós-Pelejà, Núria|||0000-0001-8923-6025
  • Santos, Juliana|||0000-0003-4148-9570
  • Blecua, Pedro|||0000-0002-1012-0300
  • Reyes Garau, Diana|||0000-0002-6124-8953
  • Armengol, Marc Antoni|||0000-0001-5206-9139
  • Fernández-Serrano, Miranda|||0000-0001-9040-8496
  • Miskin, Hari P.
  • Bosch Albareda, Francesc|||0000-0001-9241-2886
  • Esteller, M.|||0000-0003-4490-6093
  • Normant, Emmanuel|||0000-0002-0570-5072
  • Roué, Gaël|||0000-0003-0245-2257
Immunotherapy-based regimens have considerably improved the survival rate of B-cell non-Hodgkin lymphoma (B-NHL) patients in the last decades; however, most disease subtypes remain almost incurable. TG-1801, a bispecific antibody that targets CD47 selectively on CD19+ B-cells, is under clinical evaluation in relapsed/refractory (R/R) B-NHL patients either as a single-agent or in combination with ublituximab, a new generation CD20 antibody. A set of eight B-NHL cell lines and primary samples were cultured in vitro in the presence of bone marrow-derived stromal cells, M2-polarized primary macrophages, and primary circulating PBMCs as a source of effector cells. Cell response to TG-1801 alone or combined with the U2 regimen associating ublituximab to the PI3Kδ inhibitor umbralisib, was analyzed by proliferation assay, western blot, transcriptomic analysis (qPCR array and RNA sequencing followed by gene set enrichment analysis) and/or quantification of antibody-dependent cell death (ADCC) and antibody-dependent cell phagocytosis (ADCP). CRISPR-Cas9 gene edition was used to selectively abrogate GPR183 gene expression in B-NHL cells. In vivo, drug efficacy was determined in immunodeficient (NSG mice) or immune-competent (chicken embryo chorioallantoic membrane (CAM)) B-NHL xenograft models. Using a panel of B-NHL co-cultures, we show that TG-1801, by disrupting the CD47-SIRPα axis, potentiates anti-CD20-mediated ADCC and ADCP. This led to a remarkable and durable antitumor effect of the triplet therapy composed by TG-1801 and U2 regimen, in vitro, as well as in mice and CAM xenograft models of B-NHL. Transcriptomic analysis also uncovered the upregulation of the G protein-coupled and inflammatory receptor, GPR183, as a crucial event associated with the efficacy of the triplet combination. Genetic depletion and pharmacological inhibition of GPR183 impaired ADCP initiation, cytoskeleton remodeling and cell migration in 2D and 3D spheroid B-NHL co-cultures, and disrupted macrophage-mediated control of tumor growth in B-NHL CAM xenografts. Altogether, our results support a crucial role for GPR183 in the recognition and elimination of malignant B cells upon concomitant targeting of CD20, CD47 and PI3Kδ, and warrant further clinical evaluation of this triplet regimen in B-NHL.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Genome-Wide Studies in Ischaemic Stroke, Are Genetics Only Useful for Finding Genes?

  • Gallego Fabrega, Cristina|||0000-0003-3229-5512
  • Muiño, Elena|||0000-0001-5839-7328
  • Cárcel-Márquez, Jara|||0000-0002-6949-0699
  • Llucià-Carol, Laia|||0000-0002-7732-0665
  • Lledós, Miquel|||0000-0001-8832-789X
  • Martín-Campos, Jesús María|||0000-0003-0414-037X
  • Cullell, Natalia|||0000-0001-5118-1014
  • Fernández Cadenas, Israel|||0000-0003-4821-2363
Ischaemic stroke is a complex disease with some degree of heritability. This means that heritability factors, such as genetics, could be risk factors for ischaemic stroke. The era of genome-wide studies has revealed some of these heritable risk factors, although the data generated by these studies may also be useful in other disciplines. Analysis of these data can be used to understand the biological mechanisms associated with stroke risk and stroke outcome, to determine the causality between stroke and other diseases without the need for expensive clinical trials, or to find potential drug targets with higher success rates than other strategies. In this review we will discuss several of the most relevant studies regarding the genetics of ischaemic stroke and the potential use of the data generated.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Combining fMRI and DISC1 gene haplotypes to understand working memory-related brain activity in schizophrenia

  • Guardiola-Ripoll, Maria|||0000-0001-6949-5687
  • Sotero-Moreno, Alejandro
  • Almodóvar Payá, Carmen|||0000-0002-1952-1581
  • Hostalet, Noemí
  • Guerrero-Pedraza, Amalia|||0000-0001-7567-9407
  • Ramiro, Núria
  • Ortiz-Gil, Jordi|||0000-0001-7910-8062
  • Arias, Barbara|||0000-0001-9181-2132
  • Madre Rull, Mercè|||0000-0002-4660-3216
  • Soler-Vidal, Joan
  • Salvador, Raymond|||0000-0001-5557-1562
  • McKenna, Peter J.
  • Pomarol-Clotet, Edith|||0000-0002-8159-8563
  • Fatjó-Vilas, Mar|||0000-0001-9963-6241
The DISC1 gene is one of the most relevant susceptibility genes for psychosis. However, the complex genetic landscape of this locus, which includes protective and risk variants in interaction, may have hindered consistent conclusions on how DISC1 contributes to schizophrenia (SZ) liability. Analysis from haplotype approaches and brain-based phenotypes can contribute to understanding DISC1 role in the neurobiology of this disorder. We assessed the brain correlates of DISC1 haplotypes associated with SZ through a functional neuroimaging genetics approach. First, we tested the association of two DISC1 haplotypes, the HEP1 (rs6675281-1000731-rs999710) and the HEP3 (rs151229-rs3738401), with the risk for SZ in a sample of 138 healthy subjects (HS) and 238 patients. This approach allowed the identification of three haplotypes associated with SZ (HEP1-CTG, HEP3-GA and HEP3-AA). Second, we explored whether these haplotypes exerted differential effects on n-back associated brain activity in a subsample of 70 HS compared to 70 patients (diagnosis × haplotype interaction effect). These analyses evidenced that HEP3-GA and HEP3-AA modulated working memory functional response conditional to the health/disease status in the cuneus, precuneus, middle cingulate cortex and the ventrolateral and dorsolateral prefrontal cortices. Our results are the first to show a diagnosis-based effect of DISC1 haplotypes on working memory-related brain activity, emphasising its role in SZ.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Analysis of networks in the dorsolateral prefrontal cortex in chronic schizophrenia, Relevance of altered immune response

  • Vera Montecinos, América|||0000-0002-3468-0556
  • Rodríguez-Mias, Ricard
  • Vila, Èlia|||0000-0003-2790-5400
  • Villén, Judit|||0000-0002-1005-1739
  • Ramos Josemaría, Belén|||0000-0002-4577-2106
The dorsolateral prefrontal cortex (DLPFC) has a crucial role in cognitive functioning and negative symptoms in schizophrenia. However, limited information of altered protein networks is available in this region in schizophrenia. We performed a proteomic analysis using single-shot liquid chromatography-tandem mass spectrometry of grey matter of postmortem DLPFC in chronic schizophrenia subjects (n = 20) and unaffected subjects (n = 20) followed by bioinformatic analysis to identify altered protein networks in schizophrenia (PXD024939 identifier in ProteomeXchange repository). Our results displayed a proteome profile in the DLPFC of 1989 proteins. 43 proteins were found significantly altered in schizophrenia. Analysis of this panel showed an enrichment of biological processes implicated in vesicle-mediated transport, processing and antigen presentation via MHC class II, intracellular transport and selenium metabolism. The enriched identified pathways were MHC class II antigen presentation, vesicle-mediated transport, Golgi ER retrograde transport, Nef mediated CD8 downregulation and the immune system. All these enriched categories were found to be downregulated. Furthermore, our network analyses showed crosstalk between proteins involved in MHC class II antigen presentation, membrane trafficking, Golgi-to-ER retrograde transport, Nef-mediated CD8 downregulation and the immune system with only one module built by 13 proteins. RAB7A showed eight interactions with proteins of all these pathways. Our results provide an altered molecular network involved in immune response in the DLPFC in schizophrenia with a central role of RAB7A. These results suggest that RAB7A or other proteins of this network could be potential targets for novel pharmacological strategies in schizophrenia for improving cognitive and negative symptoms.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Relationship between Depressive Symptoms, Quality of Life and miRNAs 8 Years after Bariatric Surgery

  • Mela, Virginia|||0000-0001-7702-0972
  • Agüera, Zaida|||0000-0003-4453-4939
  • Alvarez-Bermudez, Maria D.
  • Martín-Reyes, Flores
  • Granero, Roser|||0000-0001-6308-3198
  • Sánchez-García, Ana
  • Oliva-Olivera, Wilfredo
  • Tomé, Monica
  • Moreno-Ruiz, Francisco J.
  • Soler-Humanes, Rocío
  • Fernández-Serrano, Jose L.
  • Sánchez-Gallegos, Pilar
  • Martínez-Moreno, Jose M.
  • Sancho-Marín, Raquel
  • Fernández Aranda, Fernando|||0000-0002-2968-9898
  • García-Fuentes, Eduardo|||0000-0002-3491-2724
  • Tinahones, Francisco J.|||0000-0001-6871-4403
  • Garrido Sánchez, Lourdes|||0000-0003-0756-9606
Background: There are conflicting results on whether weight loss after bariatric surgery (BS) might be associated with quality of life (QoL)/depressive symptomatology. We aim to determine whether BS outcomes are associated with QoL/depressive symptomatology in studied patients at the 8-year follow-up after BS, as well as their relationship with different serum proteins and miRNAs. Methods: A total of 53 patients with class III obesity who underwent BS, and then classified into "good responders" and "non-responders" depending on the percentage of excess weight lost (%EWL) 8 years after BS (%EWL ≥ 50% and %EWL < 50%, respectively), were included. Basal serum miRNAs and different proteins were analysed, and patients completed tests to evaluate QoL/depressive symptomatology at 8 years after BS. Results: The good responders group showed higher scores on SF-36 scales of physical functioning, role functioning-physical, role functioning-emotional, body pain and global general health compared with the non-responders. The expression of hsa-miR-101-3p, hsa-miR-15a-5p, hsa-miR-29c-3p, hsa-miR-144-3p and hsa-miR-19b-3p were lower in non-responders. Hsa-miR-19b-3p was the variable associated with the response to BS in a logistic regression model. Conclusions: The mental health of patients after BS is limited by the success of the intervention. In addition, the expression of basal serum miRNAs related to depression/anxiety could predict the success of BS.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The pituitary adenylate cyclase-activating polypeptide system as a sex-specific modulator of hippocampal response to threat stimuli

  • Porta-Casteràs, Daniel|||0000-0002-3921-3607
  • Cano, Marta|||0000-0003-0675-9483
  • Steward, Trevor|||0000-0003-3116-8175
  • Andero Galí, Raül|||0000-0003-3641-8903
  • Cardoner, Narcís|||0000-0001-9633-0888
Pituitary adenylate cyclase-activating polypeptide (PACAP) receptor gene polymorphism has been postulated as a potential sex-specific diagnostic biomarker of trauma-related disorders. However, no research to date has evaluated whether the PACAPergic system may act as a vulnerability/resilience neuromechanism to trauma-induced psychopathology in healthy participants without heightened risk to experience traumatic events. Here, we compared the amygdala and hippocampus response to fearful faces in participants with at-risk genotype versus non-risk participants from the Human Connectome Project (n = 991; 53.4% female). Increased hippocampal response to fearful faces in the female risk group emerged in sex by genetic risk interaction. Our findings revealed the first sex-specific neurogenetic vulnerability factor to trauma-related disorders, and emphasize the importance of prevention-based strategies to ameliorate neuropsychiatric pathophysiology.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Brewpitopes, a pipeline to refine B-cell epitope predictions during public health emergencies

  • Farriol-Duran, Roc
  • López-Aladid, Ruben
  • Porta-Pardo, Eduard|||0000-0001-7900-4239
  • Torres, Antoni|||0000-0002-8643-2167
  • Fernández Barat, Laia|||0000-0001-7528-9636
The application of B-cell epitope identification to develop therapeutic antibodies and vaccine candidates is well established. However, the validation of epitopes is time-consuming and resource-intensive. To alleviate this, in recent years, multiple computational predictors have been developed in the immunoinformatics community. Brewpitopes is a pipeline that curates bioinformatic B-cell epitope predictions obtained by integrating different state-of-the-art tools. We used additional computational predictors to account for subcellular location, glycosylation status, and surface accessibility of the predicted epitopes. The implementation of these sets of rational filters optimizes in vivo antibody recognition properties of the candidate epitopes. To validate Brewpitopes, we performed a proteome-wide analysis of SARS-CoV-2 with a particular focus on S protein and its variants of concern. In the S protein, we obtained a fivefold enrichment in terms of predicted neutralization versus the epitopes identified by individual tools. We analyzed epitope landscape changes caused by mutations in the S protein of new viral variants that were linked to observed immune escape evidence in specific strains. In addition, we identified a set of epitopes with neutralizing potential in four SARS-CoV-2 proteins (R1AB, R1A, AP3A, and ORF9C). These epitopes and antigenic proteins are conserved targets for viral neutralization studies. In summary, Brewpitopes is a powerful pipeline that refines B-cell epitope bioinformatic predictions during public health emergencies in a high-throughput capacity to facilitate the optimization of experimental validation of therapeutic antibodies and candidate vaccines.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Mechanisms modulating foam cell formation in the arterial intima, exploring new therapeutic opportunities in atherosclerosis

  • La Chica Lhoëst, María Teresa|||0000-0002-9070-5973
  • Martinez, A.
  • Claudi, Lene
  • Garcia, E.
  • Benitez Amaro, Aleyda|||0000-0002-1106-3125
  • Polishchuk, A.
  • Piñero, Janet|||0000-0003-1244-7654
  • Viladés Medel, David|||0000-0002-3638-9703
  • Guerra Ramos, José María|||0000-0001-5397-9177
  • Sanz, F.
  • Rotllan, Noemi|||0000-0002-0587-8045
  • Escolà-Gil, Joan Carles|||0000-0001-9021-2485
  • Llorente-Cortés, Vicenta|||0000-0002-0067-7201
In recent years, the role of macrophages as the primary cell type contributing to foam cell formation and atheroma plaque development has been widely acknowledged. However, it has been long recognized that diffuse intimal thickening (DIM), which precedes the formation of early fatty streaks in humans, primarily consists of lipid-loaded smooth muscle cells (SMCs) and their secreted proteoglycans. Recent studies have further supported the notion that SMCs constitute the majority of foam cells in advanced atherosclerotic plaques. Given that SMCs are a major component of the vascular wall, they serve as a significant source of microvesicles and exosomes, which have the potential to regulate the physiology of other vascular cells. Notably, more than half of the foam cells present in atherosclerotic lesions are of SMC origin. In this review, we describe several mechanisms underlying the formation of intimal foam-like cells in atherosclerotic plaques. Based on these mechanisms, we discuss novel therapeutic approaches that have been developed to regulate the generation of intimal foam-like cells. These innovative strategies hold promise for improving the management of atherosclerosis in the near future.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Combination therapy overcomes secondary PARPi resistance in ATM-deficient prostate cancer

  • Arce Gallego, Sara
  • Esquefa, Victor
  • Domènech Garcia, Heura
  • Aguilar Villalba, Daniel
  • Casals, Teresa
  • Oliveira Tercero, Anna
  • de Llobet Cucalón, Lara
  • Anselmino, Nicolás
  • Herranz, Nicolas
  • Salca, Andrei
  • Mir Arnau, Gisela
  • Simonetti, Sara
  • Brandariz, Julian
  • Casanova-Salas, Irene
  • Mateo, Joaquin
  • Serra, Violeta
Combination therapy; PARPi inhibitors; Prostate cancer, Teràpia combinada; Inhibidors de PARPi; Càncer de pròstata, Terapia combinada; inhibidores de PARPi; Cáncer de próstata, PARP inhibitors (PARPi) are approved treatments for patients with metastatic prostate cancer (mPC); tumors with homologous recombination repair (HRR) defects are particularly sensitive to this drug class. While previous work has associated ATM defects with response to PARPi, its predictive value remains controversial and the mechanisms underlying sensitivity and eventual acquired drug resistance in this setting remain unclear. To address this, we generated in vitro prostate cancer models of acquired PARPi resistance to olaparib and saruparib, a novel selective PARP1 inhibitor and pursued functional characterization and drug sensitivity studies. We found that resistant models bypass the G2/M arrest induced by PARPi in sensitive models; and display a greater reliance on the ATR-dependent response to DNA damage and replication stress, mainly through the ATR-CHK1 axis. Consistently, we demonstrate in vivo that the combination of PARPi-ATRi in resistant models restores treatment sensitivity through enhancing replication stress. Collectively, these findings highlight an interplay between ATM-ATR signaling as a key mediator of PARPi sensitivity in ATM-deficient mPC and identify a promising therapeutic combination to prolong treatment response and potentially improve patients’ outcomes., This work was supported by funding from the CRIS Cancer Foundation (grant TCL_2020-10 to J. Mateo) and Fundación AECC (LABAE20019MATE), as well as a grant from the AstraZeneca Partners of Choice program (POC5270-10045025). Sara Arce-Gallego was supported by Instituto de Salud Carlos III (FI19/00280); Irene Casanova-Salas was supported by a Prostate Cancer Foundation YIA (24YOU12); Violeta Serra received funding from an ERA PerMed grant (ERAPERMED2019-215). We also acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for the financial support to VHIO as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Program from the Generalitat de Catalunya for their support on this research. We also would like to acknowledge Dr Lara Nonell and the Bioinformatics Unit at VHIO for their support in NGS analysis and Dr Tian Tian at VHIO for providing the SceI-BFP conjugated enzyme.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors

  • Neeb, Antje
  • Herranz Martín, Nicolás
  • Arce Gallego, Sara
  • Buroni, Lorenzo
  • Athie Cuervo, Alejandro
  • Casanova Salas, Irene
  • González Rodríguez, Macarena
  • Morales Barrera, Rafael
  • Suárez Rodríguez, Cristina
  • Carles Galceran, Joan
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Miranda, Susana
  • Cordoba, Sarai
  • Castro, Natalia
  • Yuan, Wei
  • Casals, Teresa
Inhibició de l’ATR; Resposta de danys a l’ADN; Càncer de pròstata, Inhibición de ATR; Respuesta al daño del ADN; Cancer de prostata, ATR inhibition; DNA damage response; Prostate cancer, Background Deleterious ATM alterations are found in metastatic prostate cancer (PC); PARP inhibition has antitumour activity against this subset, but only some ATM loss PCs respond. Objective To characterise ATM-deficient lethal PC and to study synthetic lethal therapeutic strategies for this subset. Design, setting, and participants We studied advanced PC biopsies using validated immunohistochemical (IHC) and next-generation sequencing (NGS) assays. In vitro cell line models modified using CRISPR-Cas9 to impair ATM function were generated and used in drug-sensitivity and functional assays, with validation in a patient-derived model. Outcome measurements and statistical analysis ATM expression by IHC was correlated with clinical outcome using Kaplan-Meier curves and log-rank test; sensitivity to different drug combinations was assessed in the preclinical models. Results and limitations Overall, we detected ATM IHC loss in 68/631 (11%) PC patients in at least one biopsy, with synchronous and metachronous intrapatient heterogeneity; 46/71 (65%) biopsies with ATM loss had ATM mutations or deletions by NGS. ATM IHC loss was not associated with worse outcome from advanced disease, but ATM loss was associated with increased genomic instability (NtAI:number of subchromosomal regions with allelic imbalance extending to the telomere, p = 0.005; large-scale transitions, p = 0.05). In vitro, ATM loss PC models were sensitive to ATR inhibition, but had variable sensitivity to PARP inhibition; superior antitumour activity was seen with combined PARP and ATR inhibition in these models. Conclusions ATM loss in PC is not always detected by targeted NGS, associates with genomic instability, and is most sensitive to combined ATR and PARP inhibition., We gratefully acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence ( CEO13_2-002 ), the Prostate Cancer Foundation (including Young Investigator Awards to Joaquin Mateo, Pasquale Rescigno, and Adam Sharp), Stand Up To Cancer, and the UK Department of Health through an Experimental Cancer Medicine Centre grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Part of this work was also funded by a Deparment of Defense CDMRP Impact Award (W81XWH-18-1-0756) to Joaquin Mateo and by Instituto de Salud Carlos III through Grant FI19/00280 to Sara Arce-Gallego, Grant CP19/00170 to Nicolás Herranz, and Grant PI18/01384 to Joaquin Mateo. The authors affiliated to VHIO acknowledge the “la Caixa” Foundation ( ID 100010434 ) for funding under agreement LCF/PR/PR17/51120011 and funding from Fundacion FERO and Moventia . This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement 837900 . The funding organisations had no role in the design, conduction or data analysis of this project, neither in the manuscript preparation.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Increasing trend of antimicrobial resistance in Shigella associated with MSM transmission in Barcelona, 2020–21: outbreak of XRD Shigella sonnei and dissemination of ESBL-producing Shigella flexneri

  • Moreno-Mingorance, Albert
  • Mir Cros, Alba
  • Goterris Bonet, Lidia
  • Rodríguez Garrido, Virginia
  • Sulleiro, Elena
  • Barberà Gracia, Mª Jesús
  • Descalzo Jorro, Vicente
  • Bravo, Albert
  • Roca, Josep
  • González-López, Juan José
  • Pumarola Suñe, Tomàs
  • VIÑADO, BELEN
  • Larrosa, María Nieves
  • Hoyos Mallecot, Yannick
Antimicrobial resistance; Shigella sonnei; Sexually transmitted infection, Resistencia antimicrobiana; Shigella sonnei; Infección de transmisión sexual, Resistència antimicrobiana; Shigella sonnei; Infecció de transmissió sexual, Background Several countries have recently reported the detection of ESBL-producing Shigella sonnei associated with transmission among MSM. In a previous study by our group, 2.8% of Shigella spp. obtained from MSM in Barcelona between 2015 and 2019 were ESBL producers. Objectives To describe and characterize the emerging ESBL-producing Shigella spp. associated with sexual transmission among MSM detected from 2020 to 2021 in Barcelona, elucidating their connectivity with contemporaneous ESBL-producing Shigella spp. from other countries. Results From 2020 to 2021, we identified that among MSM, 68% of S. sonnei were XDR harbouring blaCTX-M-27 and 14% of Shigella flexneri were MDR harbouring blaCTX-M-27. WGS analysis showed that the ESBL-producing S. sonnei were part of a monophyletic cluster, which included isolates responsible for the prolonged outbreak occurring in the UK. Our data also reveal the first emergence and clonal dissemination of ESBL-producing and fluoroquinolone-resistant S. flexneri 2a among MSM. Conclusions We report an increasing trend of antimicrobial resistance in Shigella spp. among MSM in Barcelona since 2021, mainly as a consequence of the dissemination of XDR ESBL-producing S. sonnei, previously reported in the UK. These results highlight the importance of international collaborative surveillance of MDR/XDR S. sonnei and S. flexneri for rapid identification of their emergence and the prevention of the transmission of these pathogens., This work was partially supported by the ‘Ministerio de Economía y Competitividad’, ‘Instituto de Salud Carlos III’, and co-financed by the European Regional Development Fund (ERDF) ‘A Way to Achieve Europe’ (Spanish Network for Research in Infectious Diseases, grant number RD16/0016/0003) and by the Centro de Investigación Biomédica en Red (CIBER de Enfermedades Infecciosas, grant no. CB21/13/00054). A.M.M. is supported by a grant from the ‘Fondo de Investigación Sanitaria’ (Contratos Predoctorales de Formación en Investigación, grant number FI19/00315).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial

  • Carreira, Suzanne
  • Porta, Nuria
  • Arce Gallego, Sara
  • Llop Guevara, Alba
  • Bianchini, Diletta
  • Serra Elizalde, Violeta
  • Mateo Valderrama, Joaquim
  • Seed, George
Pròstata; PARP; Biomarcadors, Próstata; PARP; Biomarcadores, Prostate; PARP; biomarkers, PARP inhibitors are approved for treating advanced prostate cancers (APCs) with various defective DNA repair genes; however, further studies to clinically qualify predictive biomarkers are warranted. Herein we analyzed TOPARP-B Phase II clinical trial samples, evaluating whole exome and low-pass whole genome sequencing and immunohistochemical assays evaluating ATM and RAD51 foci (testing homologous recombination repair function). BRCA1/2 germline and somatic pathogenic mutations associated with similar benefit from olaparib; greater benefit was observed with homozygous BRCA deletion. Biallelic, but not mono-allelic, PALB2 deleterious alterations were associated with clinical benefit. In the ATM cohort, loss of ATM protein by immunohistochemistry associated with better outcome. RAD51 foci loss identified tumors with biallelic BRCA and PALB2 alteration while most ATM- and CDK12-altered APCs had higher RAD51 foci levels. Overall, APCs with homozygous BRCA2 deletion are exceptional responders; PALB2 biallelic loss and loss of ATM immunohistochemical expression associated with clinical benefit., TOPARP is an investigator-initiated trial; we are grateful for the support and funding from AstraZeneca, and for the study grants from Cancer Research UK (CRUK/11/029; C12540/A12829; C12540/A13230; C12540/A20447). ICR-CTSU also receives program grant funding from Cancer Research UK (Grant number: C1491/A15955, C1491/A25351). We acknowledge research funding for this work from Cancer Research UK, Prostate Cancer UK, the Movember Foundation through the London Movember Centre of Excellence (CEO13_2-002), the Prostate Cancer Foundation, and the UK Department of Health through an Experimental Cancer Medicine Centre (ECMC) grant. Professor Johann de Bono is a National Institute for Health Research (NIHR) Senior Investigator. The views expressed in this article are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health; research at the Royal Marsden Hospital is supported by a Biomedical Research Centre grant. Pasquale Rescigno was supported by a PCF Young Investigator Award 19YOUN19. The authors affiliated to VHIO acknowledge funding from “La Caixa” Foundation and European Institute of Innovation and Technology/Horizon 2020 (LCF/TR/CC19/52470003), Fundacion FERO and Fundacion Cellex. J. Mateo, A. Llop-Guevara and V. Serra received grants from Fundacion Cientifica AECC (LABAE16020PORTT) and an ERAPERMED2019-215. J. Mateo gratefully acknowledges funding from the European Union’s Horizon 2020 research and innovation program (Marie Skłodowska-Curie grant 837900), Instituto de Salud Carlos III (Grant PI18/01384), Fundación AECC, CRIS Cancer Foundation and the US Department of Defense CDMRP (Impact Award PC170510P1). S. Arce-Gallego Research. Downloaded from cancerdiscovery.aacrjournals.org on July 1, 2021. © 2021 American Association for Cancer Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Author Manuscript Published OnlineFirst on May 27, 2021; DOI: 10.1158/2159-8290.CD-21-0007 3 and V. Serra were supported by Instituto de Salud Carlos III (FI19/00280, CPII19/00033).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence

  • Arce Gallego, Sara
  • Romero-Lozano, Paula
  • Mir Arnau, Gisela
  • Aguilar, Daniel
  • Mast, Richard
  • Cresta Morgado, Pablo
  • Delgado-Serrano, Luisa
  • Simonetti, Sara
  • Macarena, Gonzalez
  • Marmolejo Castañeda, David Humberto
  • Morales-Barrera, Rafael
  • Semidey Raven, Maria Eugenia
  • Cordoba, Sarai
  • de Albert de Delás-Vigo, Matias
  • Planas, Jacques
  • Cuadras Solé, Mercè
  • Maldonado, Xavier
  • Casanova-Salas, Irene
  • Mas Malavila, Alba
  • Nonell, Lara
  • Dienstmann, Rodrigo
  • Nuciforo, Paolo
  • Vivancos, Ana
  • Llop-Guevara, Alba
  • Mateo, Joaquin
  • Carles, Joan
  • Suárez, Cristina
  • Serra, Violeta
Genomics; Immunofluorescence; Prostate cancer, Genòmica; Immunofluorescència; Càncer de pròstata, Genómica; Inmunofluorescencia; Cáncer de próstata, Metastatic prostate cancer (mPC) is enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine clinical implementation of next-generation sequencing (NGS) is still limited. We investigated the association between genomic and functional loss of HRR, using NGS and RAD51 immunofluorescence (RAD51-IF) in 219 primary or metastatic biopsies from 187 patients with stage IV prostate cancer. NGS showed frequent genomic alterations in TP53 (40%), AR (15%), PTEN (14%), FOXA1 (12%), MYC (10%), BRCA2 (9%), ATM (8%), and BRCA1 (2%). We pursued RAD51-IF in 206 samples; of those, 139/206 (67%) were evaluable. 21% of samples had RAD51-low score compatible with HRR deficiency (HRD). RAD51-IF showed high sensitivity (71%) and specificity (86%) for BRCA1/2 alterations. Patients with RAD51-low scores experienced longer progression-free survival (PFS) on poly(ADP-ribose) polymerase inhibitors (PARPi) or platinum chemotherapy. RAD51-IF is feasible in routine clinical samples from patients with mPC and is associated with clinically relevant HRR gene alterations., This work was funded by an Impact Award from the Department of Defense CDMRP (PC170510P1) and a grant from AstraZeneca (ESR-21-21360). The funders had no role in the design or conduction of the study and were not involved in the analysis or interpretation of results. CRIS Cancer Foundation (grant TCL_2020-10) and Fundación AECC (LABAE20019MATE) and a Department of Defense Physician Science Award to J.M. (PC220307). S.A.-G. was supported by Instituto de Salud Carlos III (FI19/00280). P.C.M. was supported by an ESMO Translational Research Fellowship, funded by BMS (any views, opinions, findings, conclusions, or recommendations expressed in this material are those solely of the authors and do not necessarily reflect those of ESMO or BMS). I.C.-S. was supported by a Prostate Cancer Foundation YIA (24YOU12). A.L.-G. was supported by an AECC grant (INVES20095LLOP), and V.S. received funding from an ERA PerMed grant (ERAPERMED2019-215). The VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for its financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment, and the CERCA Program from the Generalitat de Catalunya for their support of this research.